REVIEW article

Front. Endocrinol., 14 November 2017

Sec. Cancer Endocrinology

Volume 8 - 2017 | https://doi.org/10.3389/fendo.2017.00314

Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?

  • 1. Endocrinology, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy

  • 2. School of Human and Social Sciences, “Kore” University of Enna, Enna, Italy

Abstract

In the past few decades, the incidence of thyroid cancer (TC), namely of its papillary hystotype (PTC), has shown a steady increase worldwide, which has been attributed at least in part to the increasing diagnosis of early stage tumors. However, some evidence suggests that environmental and lifestyle factors can also play a role. Among the potential risk factors involved in the changing epidemiology of TC, particular attention has been drawn to insulin-resistance and related metabolic disorders, such as obesity, type 2 diabetes, and metabolic syndrome, which have been also rapidly increasing worldwide due to widespread dietary and lifestyle changes. In accordance with this possibility, various epidemiological studies have indeed gathered substantial evidence that insulin resistance-related metabolic disorders might be associated with an increased TC risk either through hyperinsulinemia or by affecting other TC risk factors including iodine deficiency, elevated thyroid stimulating hormone, estrogen-dependent signaling, chronic autoimmune thyroiditis, and others. This review summarizes the current literature evaluating the relationship between metabolic disorders characterized by insulin resistance and the risk for TC as well as the possible underlying mechanisms. The potential implications of such association in TC prevention and therapy are discussed.

Introduction

Thyroid cancer (TC) is a relatively rare cancer but represents one of the most common malignancies originating from the endocrine organs (). It is more frequent in women than in menand is now the third most common cancer in women under the age of 45 in highly developed countries (). Among various histotypes, differentiated thyroid carcinomas (DTCs) are the most frequent, accounting for approximately 85% of all TCs (). Increasing incidence of DTCs has been observed worldwide (–) in both men and women, although the cancer-specific mortality remains stable (, ). TC incidence has increased about twofold in some European countries (, ) and up to threefold in North America in the past decades (, ). Some studies put emphasis on the supposed “overdiagnosis” of TC consequent to the widespread use of ultrasonography and fine needle biopsy, and point out to the increasing diagnosis of papillary thyroid microcarcinomas (tumors with a diameter of 1 cm or less) (, , ). However, other studies (, ) have reported an increased incidence of TC of all sizes, suggesting that “overdiagnosis” cannot explain all the findings and that TC incidence is truly increasing. A promising hypothesis is that some rising risk factors might favor the molecular alterations typical of papillary TCs (PTCs), thus increasing its incidence.

The known non-modifiable risk factors for TC are age, sex, ethnicity, and genetic predisposition for TC (–). However, epidemiological studies suggest that TC incidence is largely dependent on modifiable risk factors, such as environmental carcinogens, diet habits, and lifestyle (). Environmental pollutants, such as heavy metals, compounds used by industries, non-anthropogenic carcinogens of volcanic origin (–), as well as dietary factors (), and obesity () are some of the putative risk factors suspected to play a role in the changing epidemiology of TC. Interestingly, this increasing incidence involves virtually only the papillary histotype, suggesting that some carcinogens may favor specific molecular abnormalities related to this histotype (, ).

Insulin Resistance, Hyperinsulinemia, and Epidemiologic and Clinical Aspects of TC: A Possible Link?

Evidence of a Positive Association between TC and Insulin Resistance

Obesity is the most common metabolic disorder associated with insulin resistance and compensative hyperinsulinemia. Obesity has more than doubled its prevalence in the past 30 years reaching a prevalence of 40% in the United States and 30% in Europe. The association of obesity with several cancer histotypes is now well established and has become an area of raising concern in oncology (). In particular, cancers associated with obesity also pose a therapeutical challenge because they tend to be resistant to conventional as well as to target treatments, to metastasize earlier and to have a worse prognosis (–). Approximately 14% of cancer-related deaths in men and 20% in women are partially attributed to obesity.

During the past two decades, several epidemiological studies, although not specifically designed for TC, have consistently suggested that a positive association exists between obesity and TC risk (Table 1). A pooled analysis of 12 case–control studies provided early evidence that body mass index (BMI) and weight at diagnosis were directly related to a higher risk for TC in women [odds ratio (OR) = 1.2 for the highest tertile], but not in men. This association was observed for both PTCs and follicular TCs and in all age groups, although there was a significant heterogeneity between the studies analyzed (). From 2001 to 2010 several single cohort, case–control, prospective cohort, and cross-sectional studies have confirmed the association between overweigh/obesity and TC risk, although the results are rather inconsistent in men, likely for the smaller number of cancer cases in men and the suboptimal adjustment for potential concomitant risk factors (–). However, a meta-analysis based on prospective observational studies, found a positive role of obesity as risk factor for TC in both sexes [relative risk (RR) of 1.33 and 1.14, respectively, for women and men, for each 5-unit increase in BMI] (). In a prospective study based on self-reported medical history, anthropometric and behavioral factors in 90,713 US radiologic technologists followed for 23 years, an elevated risk for TC was observed for women with a RR of 1.74 (95% CI: 1.03–2.94, P-trend: 0.04) for BMI ≥ 35.0 vs. 18.5–24.9 kg/m2. A similar association was found for men ().

Table 1

ConditionsReference
Insulin-resistanceRezzónico et al. ()
Bae et al. ()
ObesityRon et al. ()
Dal Maso et al. ()
Samanic et al. ()
Oh et al. ()
Engeland et al. ()
Renehan et al. ()
Brindel et al. ()
Clero et al. ()
Leitzmann et al. ()
Kitahara et al. ()
Almquist et al. ()
Rinaldi et al. ()
Kim et al. ()
Oberman et al. ()
T2DMWideroff et al. ()
Meinhold et al. ()
Chodick et al. ()
Aschebrook-Kilfoy et al. ()
Duran et al. ()
Lai et al. ()
Tseng ()
Paulus et al. ()
Yeo et al. ()
Oberman et al. ()

Studies regarding a possible association between TC risk and insulin-resistance and related disorders.

In 2011, a pooled analysis of five prospective studies including a large number of incident TC in men, and taking into account several potential risk factors, found that the risk of TC was greater with increased BMI [per 5 kg/m2: hazard risk (HR) in women 1.16 and 1.21 in men]. When considering women and men together, the HR was 1.2 and 1.53, respectively, in overweight and obese subjects. No differences were found among the TC histotypes. This pooled analysis provided the first strong support to the concept that obesity is an independent risk factor for TC in both women and men (). However, these studies have limitations, as they lack data on fat distribution, amount of lean versus fat mass, fat mass and/or insulin resistance-related biomarkers, and thyroid function parameters. These technical issues and the low HR values often reported impose caution in interpreting the biological significance of these results.

Three studies conducted in 2012 attempted to provide additional clues regarding TC association with insulin-resistance parameters (, , ). However, the results were conflicting. Two of these studies (, ) found an increased risk of TC in subjects with high waist circumference (>102 cm in men and >88 cm in women), a parameter that correlates with visceral adiposity and is a solid readout of insulin resistance. The HR was 1.79 in men () and ranged from 1.42 to 1.54 in women (), suggesting that central adiposity may impact on TC risk. In contrast, the third study (), conducted in a cohort of postmenopausal women, failed to find an association between TC risk and various adiposity parameters such as waist circumference, waist-hip-ratio, hip circumference, and BMI (). In a meta-analysis of seven cohort studies, the combined RR of TC was 1.18 (95% CI: 1.11–1.25) for overweight and obesity combined ().

Another recent pooled analysis () included 22 prospective studies investigating the association between anthropometric factors, such as waist circumference, baseline BMI, and BMI gain and the risk of TC. Data showed that all anthropometric factors analyzed were associated with an increased risk of all histotypes of TC originating from follicular cells: HR for height (per 5 cm) = 1.07; BMI (per 5 kg/m2) = 1.06; waist circumference (per 5 cm) = 1.03; young-adult BMI (per 5 kg/m2) = 1.13; and adulthood BMI gain (per 5 kg/m2) = 1.07. Associations for baseline BMI and waist circumference were mitigated after mutual adjustment (HR for waist = 1.02 and for BMI = 1.01). Furthermore, baseline BMI and BMI gain were strongly associated with anaplastic TC (ATC) and TC mortality.

A strong association between BMI and TC clinical–pathological features has been also confirmed by other studies, which found that, in patients affected by papillary TCs (PTCs), overweight and obesity were positively associated with recurrent or residual post-operative locoregional events (), extrathyroidal invasion and advanced TNM (TNM Classification of Malignant Tumors) stage (, ). Taken together, these results suggest that excess adiposity is associated with increased incidence and mortality for TC of follicular origin. However, at least one study has reported an inverse relation of BMI with stage, tumor invasion and recurrence (), suggesting that more studies are needed to better evaluate the link between TC prognosis and adiposity.

Dysregulation of Adipocytokines As a Possible Contributor to Cancer Risk in Obese Patients

Obesity is strictly associated not only with insulin resistance and hyperinsulinemia but also with a profound dysregulation of adipocytokines secretion (Figure 1). Indeed, adipose tissue has strongly been established as an endocrine organ for its ability to secrete several polypeptides, known as adipokines, which contribute to the pathogenesis of insulin-resistance and related metabolic alterations in obese patients. Two most known adipokines are leptin and adiponectin. Both of them have been studied as potential contributors to the pathophysiology of cancer associated with insulin resistance, beyond their well-known role in energy balance (). Leptin is generally up-regulated with increasing fat mass and acts as an antiappetite regulator, mainly through specific membrane receptors, the obesity receptors (Ob-Rs). Aberrant expression of leptin and/or its receptor have been found in a variety of malignancies including TC (, ). In vitro studies have shown that leptin modulates growth, proliferation and invasion of TC cell lines via activation of various prosurvival signaling pathways such as Janus kinase/signal transducers of activated transcription (JAK/STAT), phosphoinositide-3-kinase (PI3K)/protein kinase B/Akt (PKB/Akt), and/or mitogen-activated protein kinase (MAPK) (, ). However, the results have been sometimes contradictory, likely because of dependence on the cell type and cell context.

Figure 1

Adiponectin is the most abundant adipokine negatively correlated with body fat, BMI, insulin-resistance, and inflammation states (). Adiponectin binds two receptors isoforms (AdipoR1, AdipoR2) and acts as an insulin-sensitizer, anti-inflammatory and anti-tumor agent, the latter by inhibiting cell proliferation and angiogenesis and increasing apoptosis via the involvement of mammalian target of rapamycin (mTOR)/5′ adenosine monophosphate-activated protein kinase (AMPK), MAPK, JAK/STAT, and PI3K/PKB/Akt pathways (, ). So far, few studies have investigated the association between adiponectin and TC. One of these studies has shown that TC specimens and cell lines express both AdipoR1 and AdipoR2. However, in the TC cell lines evaluated, recombinant adiponectin did not exert significant biological effects ().

For both adiponectin and leptin only a limited number of in vivo studies have been performed. Serum leptin levels in papillary thyroid tumor patients were found to be significantly higher than in control subjects, and Ob-Rs expression in TC tissues was significantly associated with more aggressive tumor phenotype (, ). However, these studies did not find significant differences in BMI between cancer patients and control subjects (–).

Adiponectin levels have been found to be lower in TC patients than in controls (17.00 ± 6.32 vs. 19.26 ± 6.28 µg/ml) (). Besides, individuals in the highest tertile of adiponectin levels showed a lower risk for TC (OR = 0.29; 95% CI: 0.14−0.55) (). Conversely, in a prospective cohort study of patients with end-stage renal disease, low adiponectin levels were an independent predictor of developing cancer, with the TC being the second more common malignancy (). Yet, in a single-cohort study of patients affected by PTC, tumor expression of adiponectin receptors (both AdipoR1 and AdipoR2) was positively correlated with the tumor aggressiveness.

In summary, several studies suggest a significant association between obesity, visceral adiposity and altered adipocytokine profile with TC risk and aggressiveness. However, at least some of these studies have significant limitations with regard to study design, including lack of adjustment for potential confounders, and/or limited statistic power. Therefore, more studies are needed to confirm these conclusions. As a practical implication of these data, one study found that in obese patients with established risk factors [family history, radiation exposure, Hashimoto’s thyroiditis (HT), elevated thyroid stimulating hormone (TSH)], ultrasound screening for TC is cost-effective ().

The Interplay of Insulin Resistance with Other Putative Risk Factors for TC

Insulin Resistance and TSH

In follicular well-differentiated thyroid cells, signaling mediated by pituitary TSH represents the major pathway, which primes thyroid cells to undergo cell cycle progression, DNA synthesis, and cell proliferation (). The key role of TSH signaling in thyroid carcinogenesis is supported by large epidemiological studies showing a strong association between serum TSH levels and TC development and progression (–) (Figure 1). However, even in differentiated hystotypes, suppression of TSH is not enough to avoid or block local invasion and distant metastases. This observation suggests that the mitogenic effect of TSH on human thyrocytes is modulated by other factors including insulin, insulin growth factor-1 (IGF-1), insulin growth factor-2 (IGF-2), and epidermal growth factor (EGF) (, –).

Classically, TSH induced growth in thyrocytes occurs mainly through the TSHR-dependent increase in cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A (PKA)-dependent and -independent pathways including: cAMP/PKA/cAMP response element-binding protein (CREB), cAMP/PKA/exchange factor directly activated by cAMP 1/Ras-related protein 1(Rap1)/extracellular signal-regulated kinases (ERKs)/ETS transcription factor, protein kinase C (PKC)/nuclear factor kappa-light-chain-enhancer of activated B cells, nuclear factor κB, PKC/proto-oncogene c-Raf (c-Raf)/ERK/MAPK-activated protein kinase-1 (p90rsk), and rat sarcoma virus protein (Ras)/c-Raf/ERK cascades (–).

Moreover, full activation of mitogenesis results from the crosstalk between TSH downstream pathways with other signaling networks, such as PI3K/Akt/mTOR, serine/threonine-protein kinase B-Raf, (B-Raf)/MAPK, proto-oncogene protein Wnt-1, (Wnt)/β-catenin, activated by several tyrosine kinase receptors (RTKs) (, ). Studies carried out in normal and tumor thyrocytes have especially highlighted the importance of the functional crosstalk between TSH-cAMP and insulin/IGF axis, which occurs at multiple levels (, ).

Notably, the IGF axis plays an important role in regulating normal growth and development in the thyroid (, ), partially by modulating the expression of thyroid transcription factor 2, which mediates the transcription of thyroid specific genes such as thyroglobulin (Tg) and thyroperoxidase (TPO) (, –). As mentioned above, the crosstalk between TSH and insulin/IGF axis appears also to play a role in thyroid tumorigenesis. Indeed, in TC cells and tissue specimens, both IGF-1 receptor (IGF-1R) and insulin receptor (IR) are often overexpressed, representing an early event in thyroid carcinogenesis (, ). IR expression is also stimulated by TSH, via cAMP (). IR, exists in two isoforms (IR-A and IR-B), and in cancer is predominantly expressed as the “promitogenic” isoform A (IR-A), which binds with high affinity not only insulin but also IGF-2 (, –). In TC, the activation of the autocrine IGF-2/IR-A loop was found to correlate with cellular dedifferentiation and tumor progression and aggressiveness. Indeed, the relative abundance of IR-A is approximately 40% in normal thyrocytes and increases to over 70% in TC cells with undifferentiated or stem-like phenotype (, ) that also produce IGF-2 (). Interestingly, IGF-1R expression is also high in differentiated cancers but decreases somehow with cancer dedifferentiation (–). In agreement with these data, phosphorylated IGF-1Rs are highly expressed in the majority of TCs but tend to be low in aggressive tumors (). Interestingly, IGF-1R expression in PTC appears to be higher in patients with type 2 diabetes mellitus (T2DM) than in non-diabetic patients (). Taken together, these data suggest that both IGF-1R and IR-A play a role in TC. However, the IGF-2/IR-A loop appears to be more important than the IGF-1/IGF-1R loop in thyroid cells with dedifferentiated and stem-like phenotype () involved in tumor progression and metastasis ().

In insulin resistant subjects, the crosstalk between TSH and IGFs axis appears to be enhanced (Figure 1). In fact, obese subjects often show TSH levels at the upper limit of the normal range or slightly increased () that seem in relation with the degree of obesity and to the levels of cytokines and other inflammatory markers produced by adipose tissue, including leptin (–). Although the actual cause for the hyperthyrotropinemia in obese individuals is still unknown, several mechanisms have been proposed, including increased production of pro-TRH by leptin (), impaired feedback due to decreased T3 receptors in the hypothalamus (), changes in peripheral deiodination process of thyroid hormones (–), the adaptive response to increased energy expenditure, and chronic low-grade inflammation associated with insulin resistance ().

A relationship between TSH and insulin-resistance has been also reported in women with polycystic ovary syndrome (PCOS), where mild TSH elevation may be positively related to their metabolic phenotype (–). Yet, TSH was also positively correlated with HOMA-IR and BMI in type 2 diabetic patients and in patients with metabolic syndrome (–). Although these results have been sometimes controversial, overall they support the positive correlation between insulin resistance and increased TSH serum levels () (Table 2).

Table 2

Disorders/TC risk factorsObesityT2DMMetabolic syndromePCOS
Increased TSH levelsIacobellis et al. (), Radetti et al. () Reinehr and Andler (), Reinehr et al. () Michalaki et al. (), Sari et al. (), Javanthi et al. ()Javanthi et al. (), Javanthi et al. (), Wolide et al. (), Taneichi et al. ()Roos et al. (), Lai et al. (), Siemimska et al. (), Mehran et al. ()Mueller et al. (), Benetti-Pinto et al. (), Benetti-Pinto et al. (), Trummer et al. (), Yin et al. (), Sinha et al. ()
Iodine deficiencyLecube et al. (), Soriguer et al. (), Eray et al. ()Al-Attas et al. ()
EDCsRundle et al. (), Fierens et al. (), Lim et al. (), Lee et al. (), Wolf et al. ()Fierens et al. (), Lim et al. (), Henriksen et al. (), Lee et al. (), Lee et al. (), Wolf et al. (), Kramer et al. (), Weinmayr et al. (), Jerrett et al. (), Coogan et al. (), Lang et al. ()Lim et al. (), Lee et al. (), Lee et al. (), Wolf et al. ()Kandaraki et al. (), Akin et al. (), Tarantino et al. (), Rajkhowa et al. (), Takeuchi and Tsutsumi (), Takeuchi et al. (), Miao et al. ()
AITMichalaki et al. (), Rotondi et al. ()Akbar et al. (), Yasmin et al. (), Toulis et al. (), Sarfo-Kantanka et al. ()Al Saab and Haddad (), Janseen et al. (), Menon and Ramachandran (), Garelli et al. (), Kachuei et al. (), Sinha et al. (), Novais Jde et al. (), Arduc et al. (), Ganie et al. ()
Thyroid angiogenesisWang et al. ()

Studies showing a possible interplay between insulin resistance related disorders and some TC risk factors.

Hyperinsulinemia itself, a major characteristic of insulin-resistant patients, is considered a determinant of cancer initiation/progression in diabetic/obese patients (, ). In the animal model, several studies carried out in hyperinsulinemic male mice overexpressing a dominant-negative, kinase-dead IGF-1R in muscle (MKR mice), have supported the important role of chronic hyperinsulinemia in cancer progression (, ). Notably, hyperinsulinemia may increase the growth of orthotopic mammary tumors through direct stimulation of the IR and without the involvement of the IGF-1R (). However, no such studies have specifically addressed the role of hyperinsulinemia in TC.

Hyperinsulinemia may increase the bioavailability of IGF-1 and IGF-2 by inhibiting the synthesis of IGF-binding protein 1 and 2 and by intensifying IGF-1 hepatic production. The increased bioavailability of IGFs may contribute to tumor progression through the stimulation of IGF-1R, IR/IGF-1R hybrids, and IR-A itself (). Yet, hyperinsulinemia, by directly activating IR-A, may favors its “non metabolic” functions and the induction of the pro-mitogenic MAPK/mTOR branch. Non-classical molecular partners, such as discoidin domain receptor 1 and G protein-coupled estrogen receptor, can be further recruited by the IGF system activated receptors, thereby favoring cancer cell proliferation and migration (–).

Taken together, these studies suggest that, in insulin-resistant patients, the concomitance of increased TSH levels, deregulation of the IGF axis, and hyperinsulinemia, may represent significant risk factors for TC.

Insulin Resistance and Thyroid Angiogenesis

Recently, a study has suggested that insulin-resistance may affect the growth and progression of thyroid nodules by increasing angiogenesis and intranodular vascularization (Figure 1) (). Indeed, it was found that insulin-resistance and high HbA1c are positively associated with a predominant intranodular flow, and with velocity, pressure and density of intranodular blood vessels, especially in nodules of large size () (Table 2). The molecular mechanisms responsible for these findings warrant further investigation. However, it is possible to speculate that insulin may stimulate vascular endothelial growth factor (VEGF) expression and promote proliferation of vascular endothelial cells in thyroid nodules and tumors, as shown in other contexts (). In line with these findings, in breast cancer patients, both hyperinsulinemia and hyperglycemia may stimulate the secretion of pro-inflammatory factors, such as tumor necrosis factor-α, tumor growth factor-α, tumor growth factor-β, interleukin-8, fibroblast growth factor-2, and VEGF-α, thus contributing to tumor neoangiogenesis (185).

Insulin Resistance and Iodine Deficiency

Iodine is essential for the synthesis and regulation of thyroid hormones. The relationship between iodine intake and TC is complex, as both iodine deficiency and iodine excess have been related to TC development (186, 187). Long-term iodine deficiency has especially been associated with follicular and anaplastic histotypes but also with the papillary histotype (188–190). In animal models, iodine deficiency acts as a weak initiator but a strong promoter of TC, mainly of the follicular type (187). The mechanisms linking the association between iodine deficiency and TC are multiple. Severe iodine deficiency may cause increase of TSH levels (191). However, iodine deficiency could per se favor angiogenesis in TC tissues by increasing VEGF mRNA expression (192) through the activation of the transcription factor hypoxia inducible factor 1a (192). In TC, iodine deficiency may also activate additional signals such as the mTOR/p70S6K pathway (193). Low iodine levels may also promote TC development favoring H2O2-mediated radical reactive oxygen species (ROS) generation, which could result in DNA damage and somatic mutations (191).

Iodine deficiency is also linked to insulin resistance. Several lines of evidences have shown that urinary iodine, which is roughly equal to iodine intake, is markedly decreased in T2DM and obese patients as compared to control subjects, and is negatively correlated with glucose, insulin concentrations and HOMA-IR index (–, 194, 195) (Table 2). The physiological pathways connecting insulin resistance with iodine status and the molecular mechanisms by which obese individuals show a reduction in urinary iodine levels are still unclear. It has been proposed that inflammatory cytokines secreted by adipose tissue of insulin resistant patients as well as hyperinsulinemia itself may negatively modulate the expression of sodium/iodine symporter (NIS) on the apical surface of enterocytes, thus inducing a decrease in iodine absorption (). Taken together, these findings suggest a functional association between iodine deficiency and insulin resistance (Figure 1). However, further studies are needed to better clarify the mechanisms underlying this relationship.

Insulin Resistance and Endocrine Disrupting Chemicals (EDCs)

Various environmental compounds either natural or synthetic, act as EDCs. These substances may affect hormone signaling through different mechanisms. In the thyroid, they may act at different levels: they may interfere with the hypothalamic–pituitary–thyroid axis, induce direct thyroid cell damage, alter peripheral metabolism of thyroid hormones, and/or affect thyrocytes proliferation, increasing the susceptibility to develop DTCs (196). Recently, it has been found that in the volcanic area of Sicily, DTC incidence is abnormally increased possibly through chronic exposure to EDCs of volcanic origin (197), supporting data reported in other volcanic areas (198).

Beyond their intrinsic carcinogenic potential, some EDCs at the concentration found in human plasma, may lead to disturbances in glucose and fat metabolism. Indeed, they alter pancreatic β-cell function in cellular and animal models (199) and inappropriately regulate intracellular lipid homeostasis as well as proliferation and differentiation of adipocytes (200). These observations suggest that some environmental EDCs may represent a risk factor in the etiology of T2DM and other metabolic disorders, particularly in pre-diabetic individuals (199). In support of these evidences, several biological and epidemiological studies have correlated EDCs exposure with obesity, metabolic syndrome, T2DM and other diseases related to insulin-resistance, including cancer (Figure 1) (201, 202) (Table 2). Recently, it has been found that long-term exposure to air pollution is associated with an increase in HOMA index and insulin levels (, 202). Some EDCs, including certain metals, by disrupting estrogen homeostasis or by mimicking estrogen actions, may lead to a pregnancy-like metabolic state characterized by insulin-resistance and hyperinsulinemia (199). Furthermore, estrogens potentiate insulin proliferative effects (203). Therefore, EDCs may contribute to DTC initiation and progression (204). The observation that DTC is 3-fold more frequent in women than in men (205) support the pivotal role of estrogens in DTC etiopathogenesis. Indeed, 17-β estradiol (E2) is a potent stimulator of benign and malignant thyrocytes, and both estrogen receptor α (ERα) and ERβ are expressed in DTCs (206). Moreover, as it has been seen in other cellular contexts (207–210), it is likely that also in thyrocytes EDCs may induce membrane-initiated rapid signals involving androgen receptors (ARs) and ERs, both of which crosstalk with the IGF axis (211).

In summary, long-term exposure to EDCs is linked to TC development and progression by multiple mechanisms that include direct toxic effects, estrogen-like effects, and worsening of insulin-resistance (Figure 1).

Insulin Resistance and Chronic Autoimmune Thyroiditis (AIT)

The association between AIT and DTC has long been a topic of controversy. Data available so far are conflicting. The coexistence of these two diseases has been reported by numerous studies ranging from 0.5 to 30% (212). A meta-analysis conducted by Singh et al. (213) demonstrated that the incidence rate of HT, the most common AIT, is 2.8 times higher in patients with PTC than in patients affected by benign thyroid diseases, and that patients with HT were affected by PTC twice as often as expected. However, many of the published studies are retrospective, had used variable histological methodologies and definitions and have been subjected to several selection biases. Furthermore, it should be underlined that population-based fine needle aspiration biopsy studies have not confirmed this relationship between HT and DTC (214).

The presence of chronic inflammation in HT acting as an initiating factor in carcinogenesis could represent a potential mechanism responsible for the link between HT and PTC. Moreover, the increase in TSH levels or in TSH receptor stimulating antibodies (TSAb), the imbalance in the amount of chemokines and cytokines favoring a switch from Th2 to Th1 immune response or the presence of insulin-resistance, may provide additional explanations for this association (215, 216).

A link between insulin-resistance and AIT has been reported by several studies (Table 2; Figure 1). For instance, it has been seen that the prevalence of AIT in insulin-resistant individuals is higher compared to normal control subjects. For instance, in PCOS patients, anti-TPO antibodies are present in 19.6–26.9% when compared with 3.3–8.3% of control patients (, –), whereas the prevalence of AIT ranges from 10 to 43% in T2DM patients (–) and from 12.4% (in children) to 10–16% (in adults) in obese patients (, ). Recently, obesity has been proposed to be a risk factor for thyroid autoimmunity (217). Data showed a positive correlation between leptin and AIT (r = 0.26; P < 0.001), independent of BMI and fat mass, suggesting the hypothesis that high leptin levels may enhance autoimmune thyroid reaction in a context susceptible to Th-1 immune response (217). Despite these intriguing results, some controversy does remain concerning whether and how insulin resistance prompts the development of AIT. So far, available studies have several limitations, such as restricted number of subjects, biases in the selection of patients and controls, differences in study design, and variability in the use of commercially available assays for anti-TPO antibodies.

Insulin Resistance in the Context of T2DM

Type 2 diabetes mellitus is characterized not only by insulin resistance but also by hyperglycemia with oxidative stress and advanced glycation end products on proteins and macromolecules, as well as by dyslipidemia and chronic low-grade inflammation (218). In some studies T2DM has been associated with increased risk for TC, although the association ratio values were low (, , 219). Indeed, a recent pooled analysis, including five prospective studies from the USA, showed that the hazard ratio for TC was 1.19 (95% CI: 0.84–1.69) in women and 0.96 (95% CI: 0.65–1.42) in men () (Table 1).

Many studies have shown an association between glucose metabolism disorders and thyroid morphologic changes in terms of gland echogenicity, goiter and nodules prevalence, and TSH levels (220–223). In a prospective study, T2DM patients showed higher TSH levels than controls (224). T2DM patients had also larger thyroid volumes and an increased prevalence of nodules. Conversely, in a retrospective survey of 1,559 patients with a new diagnosis of TC (from the continuous National Examination Survey, NHANES) an increased prevalence of T2DM was found among patients who were ≤44 years old as compared to control patients (RR 2.32, CI: 1.37–3.66) ().

Two longitudinal studies showed that a history of T2DM, ascertained by a self-administered questionnaire, is a risk factor for TC (, ). In the total cohort, the increase in TC risk was irrelevant, but it was significantly increased in women (HR. 1.46, 95% CI: 1.01–2.10). Case–control and cohort studies conducted in Unites States (, , , 225), Canada (226), Europe (, 227–230), and Asia (231, 232), confirmed an increased TC risk of approximately 20% in diabetic patients, independently of geographic region, study design, and quality analysis. Despite of a high heterogeneity among studies, the observation that the risk is increased among diabetic women, but not among men, has been always confirmed (, , 233). However, the TC risk associated with DM is more evident in the geographic areas of the world with high rates of TC.

A recent study based on a large prospective cohort, the Women’s Health Initiative, reported data at variance with previous results. In this study, 147,934 cancer free women at baseline were followed up for a median time of 15.9 years. No significant association was found between occurrence of TC with diabetes or diabetes treatment (234). Possible explanations for these negative findings include a weak association between TC and diabetes in postmenopausal women, and the lack of information for insulin resistance and hyperinsulinemia. TC risk is also increased in metabolic syndrome characterized by long-standing insulin resistance, confirming the fundamental role of elevated insulin and glucose levels in the pathogenesis of this association (235). Nevertheless, studies on TC risk in T2DM have some limitations because data regarding the metabolic control, the duration of DM, or the presence of chronic complications, have not always been evaluated. Moreover, confounding elements such as treatment, age of patients, comorbidities like obesity, have not always been appropriately taken into account in some studies. For these reasons, results are somehow controversial and should be interpreted with caution.

Several potential mechanisms can be taken into account to explain the association between T2DM and TC including the higher prevalence of abnormal serum TSH levels (236), the effects of elevated insulin and/or glucose levels in affecting cellular energy metabolism [by increasing the intracellular adenosine triphosphate (ATP)/adenosine monophosphate ratio and inactivating AMPK] (237) and immune system (by increasing ROS production and especially nitric oxide) (237, 238) (Figure 1). Moreover, it has been suggested that chronic treatment with some antidiabetic drugs, may favor the association between T2DM and cancer (239).

Clearly, insulin therapy causes chronic peripheral hyperinsulinemia, and several studies have attempted to clarify whether long-term treatment with insulin or insulin analogs may increase the risk of overall cancer mortality and incidence in patients with T2DM (240, 241). Although some studies have suggested that, unlike native insulin, the long-acting insulin analog glargine could be associated with a higher risk for cancer, especially breast cancer (241–246), re-analysis of these data, as well as further studies have found no differences in cancer risk for insulin glargine as compared with native insulin or other insulin analogs (240). Therefore, there is no clear recommendation regarding the use of insulin or insulin analog in relation to cancer risk.

The possible role of insulin secretagogues (sulfonylureas, glinides) has also been studied. Sulfonylureas (SUs) (glibenclamide, glipizide, and glimepiride) are widely used in diabetic patients. Binding to sulfonylurea receptor 1 on pancreatic beta cells, they stimulates insulin release from the intracellular vesicles. Being potent stimulators of insulin secretion, in principle, sulfonylureas might increase cancer risk. However, epidemiological studies have given controversial results sometimes showing increased cancer risk (243, 247–249). Less potent insulin secretagogues, such as glinides do not appear to be associated with cancer risk (250–253). In any case, none of the above-mentioned studies has focused on TC.

Incretin-based therapies include glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl-peptidase-4 inhibitors, both of which amplify the insulin response to glucose besides having pleiotropic effects. Therapy with GLP-1R agonists has been recently linked to the C-cell hyperplasia and increased medullary, but not follicular, TC in rodents (245, 254). However, this effect has been observed after lifetime exposure to supratherapeutic doses (255). Moreover, as human thyroid tissues express very low levels of GLP-1R this risk seems to be irrelevant. Data from human observational studies and clinical trials have yielded inconclusive results, thus, continuous monitoring of this issue is still required. Patients with T2DM often follow combination therapies with multiple drugs, making these epidemiological studies very difficult. Moreover, many studies have not taken into account the length of treatment, thus introducing time-related bias.

Two main classes of antidiabetic drugs, thiazolidinediones (TZDs) and biguanides act by reducing insulin resistance (insulin sensitizers). Their possible role in TC is discussed below.

Other antidiabetic drugs, such as alpha-glucosidase inhibitors or SGLT-2 inhibitors, do not directly affect insulin levels or insulin resistance. In any case, no data regarding the use of these drugs and the risk of TC are available.

Possible Implications for TC Prevention and Therapy

Insulin resistance is multifactorial, and genetic factors account for a significant proportion of insulin resistant subjects (256–262). However, physical inactivity and visceral obesity are the most frequent preventable causes of insulin resistance (263–265).

While the underlying biological mechanisms remain to be investigated, insulin resistance seems to be worsened by iodine deficiency in obese and diabetic patients (–, 194, 195). Moreover, evidences showing that TSH and estrogens potentiate the growth effects of insulin, lend support to the hypothesis that insulin resistance may significantly affect the risk of TC, especially by interacting with subclinical hypothyroidism, iodine deficiency, and endocrine disruptors with either estrogen-like or antithyroid activity (Figure 1). At least two of these factors, insulin resistance and environmental contamination with endocrine disruptors have been steadily rising in the past decades (204, 266) and it is reasonable to hypothesize that the interplay among these factors may contribute to the worldwide increase of PTCs incidence (, , , ).

Prevention and therapy of visceral obesity and of related disorders, such as T2DM and metabolic syndrome, are the mainstay to limit the spread of insulin resistance in the population. To this aim, and to reduce associated disorders including cancer, several international organizations and scientific societies have issued guidelines that recommend a healthy lifestyle consisting of constant physical activity and a correct diet (267–270). It is worth noting that these lifestyle changes are difficult to attain and maintain for most people and that only a small proportion of obese subjects is able to achieve significant weight loss by these measures. However, relatively small weight losses may bring about significant amelioration of insulin resistance (271, 272). Whether reduction of insulin resistance achieved by lifestyle changes is associated with reduced TC risk is currently unknown.

Exposure to environmental risk factors, such as iodine deficiency and contamination with endocrine disruptors, should be considered as well. Although iodine prophylaxis with iodized salt is now established in most countries, borderline low iodine intake can be still observed, especially in countries where iodine prophylaxis is facultative (187, 273).

Similarly, environmental monitoring for EDCs may reveal geographic areas and places with high EDC contamination (204). Clinical, ultrasound and biochemical screening can now easily diagnose autoimmune thyroid disorders that may also be associated with TC.

The identification of these additional risk factors may allow the recommendation of individualized strategies for TC prevention.

Insulin Sensitizers: A Possible Role in TC Prevention and Therapy

As stated above, only a minority of patients succeeds to change lifestyle and achieve long-lasting weight loss. Therefore, the use of insulin sensitizers has been proposed to reduce insulin resistance and its complications.

Metformin

Metformin is by far the insulin sensitizer most studied in cancer prevention and therapy. A primary effect of metformin is the suppression of the hepatic gluconeogenesis and glucose output, and to increase the peripheral glucose uptake, with consequent reduction in insulin resistance and circulating insulin levels (274).

Interestingly, the use of metformin in diabetic patients has been associated with a lower risk for cancer. A recent meta-analysis of 11 independent studies found an overall 30% statistically significant decrease in cancer risk in patients treated with metformin compared with other diabetic treatments with a promising trend for reduction in overall cancer mortality (275). Similar reductions in cancer risk and mortality was also observed in a second meta-analysis that included 32 articles (276). These and other studies have made a good case for metformin repurposing in cancer chemoprevention. However, a note of caution comes from the fact that these studies regard only diabetic patients, are all retrospective, and results need to be adjusted for multiple variables (277).

Moreover, no specific data on TC were available in these studies, although a recent study performed in Taiwan has shown that the risk of TC is also reduced in diabetic patients treated with metformin (278). However, a second case–control study (279) was unable to find a reduced risk for TC in diabetic patients taking metformin.

In some studies, the use of metformin seems to inhibit the growth of thyroid nodules, which is among risk factors for TC (280–282). In one study, the association of metformin to l-thyroxine was shown to inhibit the growth of thyroid nodules more effectively that l-thyroxine alone (280). In another randomized placebo-controlled clinical trial the use of metformin was also associated with the reduction of small solid thyroid nodules (281). Notably, a recent study showed that metformin therapy in subjects with insulin resistance was effective in decreasing thyroid volume and nodule size (282).

Multiple mechanisms may account for the chemopreventive and anticancer effects of metformin in several cancer histotypes and in TC in particular (283, 284). Relevant to thyroid, additional in vivo effects of metformin that may be linked with chemoprevention of TC may include lowering of TSH serum levels in diabetic patients (285). In fact, metformin potentiated the effect of l-thyroxine in reducing thyroid nodule volume in patients with multinodular goiter (280). However, there is evidence that the TSH lowering effect of metformin is seen only in patients with treated hypothyroidism, but not in euthyroid patients (286). Further studies are needed to fully clarify the potential of metformin as chemopreventive drug in non-diabetic, insulin resistant, euthyroid patients.

As an additional mechanism, sex steroids and sex steroid-mimicking EDCs may induce membrane-initiated signals involving AR and ERs and activation of the IGF system (211, 287). These effects have been demonstrated in prostate cancer cells, but may also operate in other cells sensitive to sex hormones. Interestingly, these membrane-initiated signals may be inhibited by metformin (288), thus supporting the potential role of metformin in cancer chemoprevention.

Apart for its possible role in cancer prevention metformin may also play a role in cancer treatment.

Anticancer actions of metformin are partially ascribed to its ability to activate the liver kinase B1/AMPK pathway and to suppress ATP production through the inhibition of mitochondrial complex I (289–292). Both actions of metformin contribute to the inhibition of the mTOR pathway, a major regulator of cell growth and proliferation (277). Metformin may also inhibit ERK signaling (293) and Ca(2+)-dependent PKC-alpha/ERK and JNK/activator protein 1 pathways (294, 295). It may also reduce Akt activity through serine phosphorylation of IRS-1 (296).

Other effects include the inhibition of transcriptional activity of CREB transcriptional factor (297) through the induction of the AMPK-dependent phosphorylation of CREB cofactor CRTC2 at Ser171, which causes CRTC2 sequestration in the cytoplasm by binding with 14–3–3 proteins (298, 299). In fact, dephosphorylated CRTC2 translocates into the nucleus, where it contributes to the CREB-dependent transcription by stimulating the formation of the complex CREB—CREB-binding protein—CRTC2 (297).

Notably, in metformin-treated patients, intraparenchimal metformin concentrations are generally significantly higher than metformin concentration in the bloodstream. For example, metformin concentration at the level of the portal vein is much higher than in the peripheral circulation, thus exposing liver to very high metformin levels (300). Many other organs, including salivary glands, stomach, small intestine, kidney as well as other organs/tissues are also able to concentrate metformin in dependence of the expression of organic cation transporters (OCTs), such as OCT1–2–3 and organ-specific metformin metabolism (301). Metformin also concentrates in the mitochondrial matrix by approximately 1,000-folds (302). These high concentrations are believed to play an important anticancer role (302, 303).

In TC cell lines, metformin was able to inhibit proliferation, through the downregulation of cyclin D1 expression and activation of AMPK, which in turn inhibits the p70S6K/pS6 signaling pathway. Moreover, in undifferentiated TC cells cultured as thyrospheres and enriched in stem-like cells, metformin inhibited the effects of insulin on growth and sphere formation, and potentiated the inhibitory effects of doxorubicin and cisplatin (304). The ability of metformin to potentiate the cytotoxic effects of chemotherapeutics via AMPK and p53 signaling was confirmed in other studies (305–307). In addition, metformin may inhibit the growth, migration and mesenchymal transition of TC cell lines by inhibiting mTOR (308). Han et al. showed that metformin elicited a dual antiproliferative effect on primary thyroid cultures and TC cells both by reducing circulating insulin and by directly inhibiting cell cycle progression and survival (304). Accordingly, DTCs occurring in metformin-treated diabetic patients were found to be significantly smaller and with increased progression-free survival as compared with the non-metformin groups (309). A higher remission in patients with TCs with cervical lymph node metastasis has also been observed (310).

Taken together, these data suggest that metformin might play a role in prevention and treatment of thyroid nodules and cancer in insulin resistant patients. Several clinical trials are currently under way with the aim to evaluate the efficacy of metformin as an add-on therapy for patients with various cancer histotypes, but none of these is focused on TC (Clinicaltrials.gov).

PPAR-γ Agonists

Thiazolidinediones, also known as glitazones, bind and activate the nuclear receptors PPAR-γ acting as agonists. They are potent insulin sensitizers used in the treatment of patients with T2DM (311). Although both metformin and TZDs decrease hepatic glucose production (312, 313), only TZDs reduce liver fat content (312, 314) and diminish fasting free fatty acid concentrations (315) thus improving skeletal muscle insulin sensitivity and reducing liver steatosis. However, side effects of TZDs, such as weight gain and fluid retention that can precipitate cardiac failure and bone fractures, have limited their use in clinical practice. Troglitazone and rosiglitazone (RGZ) were withdrawn because of hepatotoxicity (316) and suspected to increase cardiovascular risk (317), respectively. In addition, the benefit–risk ratio of pioglitazone (PIO) has been reassessed recently in light of a putatively increased risk of bladder cancer.

In a population-based study (318), it has been found that RGZ was associated with a 30–50% reduced risk of TC. In dose response analysis, the adjusted hazard ratios (95% confidence intervals) were significant for the third tertile of duration of therapy (≥14 months) and cumulative dose ≥1,800 mg (0.53, CI 0.31–0.89) and for age ≥50 years (0.50, CI 0.29–0.87) (318). However, a successive study using PIO did not show the same protective effect on TC risk, even if some limitations related to the patients classification or the presence of confounding factors cannot be excluded. However, the different results obtained with the two glitazones (RGZ and PIO) suggested that, apart from restoring insulin-sensitivity, the two drugs might have differential mechanisms on cancer (319) and thyroid cells (320).

Inhibitors of Insulin/IR-A Signaling

Several studies have highlighted the importance of the insulin/IGF-2/IR-A pathway as a potential target in tumors addicted to this signaling (, ). However, for several reasons, targeting this pathway in cancer treatment is not simple. In particular, it is now well accepted that IR and its homolog IGF-1R are functionally interconnected by forming hybrid receptors with an important role in cancer (321), and that targeting either IR or IGF-1R alone results in increased activity of the homolog receptor (322) and resistance to treatment. However, various strategies have been developed to target the insulin/IGF-2/IR-A pathway. Whether these approaches may have specific benefits in insulin resistant patients with cancer is unknown.

In order to avoid or minimize the severe derangement of the glucose metabolism associated with inhibition of total IR, future therapies should possibly aim at specific targeting of IR-A. However, specific antibodies or other drugs able to inhibit the IR-A and not the IR-B are not available and difficult to obtain because of the small differences between the two IR isoforms (323).

The identification of mutations in splicing factors in several malignancies (324, 325) has led to the development of drugs able to counteract the effects of these mutated splicing factors (326, 327). However, whether such drugs may inhibit IR-A formation and favor the IR-B isoform in TC is unknown. Another possible approach is to take advantage of the differential regulation of IR isoform protein maturation. Indeed, furin and paired basic amino acid-cleaving enzyme 4 enzymes, seems to be differentially required for IR-A and IR-B maturation (328, 329), and furin can be inhibited by a number of polyphenols (330).

Finally, various miRNAs have been found to be dysregulated in obesity and insulin resistance (331). Studies are needed to assess whether some of these miRNAs may play a role in the altered IR-A expression in cancer and whether they could be useful tools to normalize the IR-A:IR-B ratio.

Currently available small molecule TK inhibitors lack specificity for IR-A, but are able to coinhibit the IR and IGF-1R. The most studied drugs in this category are Linsitinib (OSI-906) and BMS-754807. Preclinical data, showing a significant efficacy of both drugs either alone or in combination therapies (332), have prompted several phase I–III studies—https://clinicaltrials.gov/ct2/results?term=linsitinib&pg=1 and https://clinicaltrials.gov/ct2/results?term=BMS-754807+&Search=Search. However, no definite evidence of efficacy in a clinical setting has been demonstrated so far.

A different approach for malignancies driven by the IGF-2/IR-A loop is to block IGF-2 using specific antibodies or specific ligand traps. A specific trap for IGF-2 can be obtained using a soluble preparation of the high-affinity domain 11 of M6P/IGF-2R (333, 334), while the soluble form of the IGF-1R combined with the Fc portion of IgG1 can provide a trap for both circulating IGF-1 and IGF-2 (335). These therapies have the advantage to block IR-A stimulation by IGF-2 without impairing the metabolic effects of insulin. However, they do not inhibit the effects of high circulating insulin levels in insulin resistant patients. Preclinical studies are encouraging but clinical data are lacking (335). So far, no studies have addressed the question whether inhibition of the insulin/IGF-2/IR-A signaling by these approaches may provide benefits to patients with TC in the context of insulin resistance.

Summary and Perspectives

Several lines of evidence now support the concept that the activation of the insulin/IR axis plays a role in TC carcinogenesis. In particular, various dysmetabolic conditions characterized by insulin resistance are significantly associated with an increased risk and worse prognosis of TC. Whether and to what extent insulin resistance plays a role in the worldwide, steady increase in PTCs has not been clarified yet. Indeed, several clinical studies performed until now, have reported only a positive association rather than a causative role. Moreover, some of these studies show significant limitations, including lack of adjustment for potential confounders, and/or limited statistic power and/or low OR values. These limitations should be taken into account when considering the physiological/biological significance of these studies. Similarly, more studies are required to elucidate the possible interactions between insulin resistance/hyperinsulinemia and more established TC risk factors, such as radiations, iodine deficiency, endocrine disruptors, and inflammation. Finally, how obesity derived cytokines, and overactivation of the insulin/IGF axis may affect the molecular pathways involved in the pathogenesis of TC should be explored in depth.

However, as for other malignancies associated with insulin resistance, it is to be expected that a correct lifestyle, which includes a healthy diet and physical activity, aimed at preventing obesity and T2DM would exert a beneficial effect also in TC occurrence. For all people living in iodine deficient areas, iodine prophylaxis is mandatory in order to avoid the growth promoting effect of reduced iodine intake on the thyroid gland. It could be hypothesized that additional attention should be lent to people with concomitant insulin resistance in order to avoid the combined effects of hyperinsulinemia and iodine deficiency. In T2DM patients, administration of insulin sensitizers or inhibitors of SGLT2 (336, 337) should be preferred to insulin stimulating drugs and insulin itself. Hopefully, these assumptions will be validated by future studies, although, because of the indolent natural history of most DTCs, such studies may prove to be difficult to perform.

As far as therapy is concerned, surgery, radioactive iodine treatment and TSH suppression by l-thyroxine administration are the cornerstones of DTC treatment. However, no specific therapy exists for poorly differentiated or undifferentiated TCs that have lost the ability to uptake radioiodine. Drugs with multikinase inhibiting activity are increasingly used in these cancers, but so far their effect on cancer mortality is at best uncertain (338). Clearly, new combined therapies are urgently required for these aggressive cancers. Evidences showing that the insulin/IGF axis is frequently activated in these tumors owing to overexpressed IR and IGF-1R and increased local production of IGFs lend support to the possibility that therapies targeting this axis could have a role in these new approaches. The increased awareness that overexpression of IR-A possibly plays a more important role than IGF-1R and may compensate for IGF-1R inhibition, strongly suggests that dual IR and IGF-1R inhibitors should be more efficacious than specific inhibitors of IGF-1R. Moreover, future approaches may explore the efficacy of drugs specifically targeting IR-A or pathways preferentially activated by the IGF-2/IR-A loop. Finally, insulin sensitizers able to reduce peripheral insulin levels could have a role on both prevention and treatment of TC. Certainly, more studies are needed to address the role of insulin and insulin resistance in better and individualized programs of TC prevention and adjuvant therapies. More in general, in spite of several lines of evidence indicating that obesity/insulin resistance-driven mechanisms are associated with cancer development and progression, specific guidelines for cancer prevention and treatment in these patients are lacking and should be considered a desirable aim of precision medicine.

Statements

Author contributions

VV, RM, MN, and AB: substantial contributions to the conception and design of the article; drafting the work; final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. VV, RM, and AB: revising it critically for important intellectual content.

Funding

This work was supported in part by grants from AIRC IG 19242 to AB; Ministero della Salute, Italy (grant 67/GR-2010-2319511) to RM.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

AIT, autoimmune thyroiditis; cAMP, cyclic adenosine monophosphate; AMPK, 5′ adenosine monophosphate-activated protein kinase; ATC, anaplastic thyroid cancer; ATP, adenosine triphosphate; BMI, body mass index; B-Raf, serine/threonine-protein kinase B-Raf; CBP, CREB-binding protein; CRCT2, CREB regulated transcription coactivator 2; CREB, cAMP response element-binding protein; DTC, differentiated thyroid cancer; E2, 17-beta estradiol; EDCs, endocrine disrupting chemicals; EGF, epidermal growth factor; ERKs, extracellular signal-regulated kinases; FGF-2, fibroblast growth factor-2; GPER, G protein-coupled estrogen receptor; HR, hazard risk; HT, Hashimoto’s thyroiditis; IGF-1, insulin growth factor 1; IGF-2, insulin growth factor 2; IL-8, interleukin-8; IR, insulin receptor; JAK/STAT, janus kinase/signal transducers of activated transcription;MAPK, mitogen-activated protein kinase; OR, odds ratio; p90rsk, MAPK-activated protein kinase-1; OCT, organic cation transporter; PCOS, polycystic ovary syndrome; PIO, pioglitazone; PI3K, phosphoinositide-3-kinase; PKC, protein kinase C; PTC, papillary thyroid cancer; PKA, protein kinase A; PKB/Akt, protein kinase B/Akt; c-Raf, proto-oncogene; Rap1, Ras-related protein 1; Ras, rat sarcoma virus protein; RGZ, rosiglitazone; ROS, reactive oxygen species; RR, relative risk; RTKs, tyrosine kinase receptors; TC, thyroid cancer; T2DM, type 2 diabetes mellitus; Tg, thyroglobulin; TPO, thyroperoxidase; mTOR, mammalian target of rapamycin; TSH, thyroid stimulating hormone; TZDs, tiazolidinediones; VEGF, vascular endothelial growth factor; Wnt, proto-oncogene protein Wnt.

References

  • 1

    HundahlSAFlemingIDFremgenAMMenckHR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer (1998) 83(12):2638–48.10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1

  • 2

    Thyroid Cancer Facts and Figures. National Cancer Institute Surveillance, Epidemiology, and End Results Program. (2015). Available from: http://seer.cancer.gov/statfacts/html/thyro.html

  • 3

    PathakKALeslieWDKlonischTCNasonRW. The changing face of thyroid cancer in a population-based cohort. Cancer Med (2013) 2(4):537–44.10.1002/cam4.103

  • 4

    DaviesLWelchHG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 295(18):2164–7.10.1001/jama.295.18.2164

  • 5

    ChenAYJemalAWardEM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer (2009) 115(16):3801–7.10.1002/cncr.24416

  • 6

    BlombergMFeldt-RasmussenUAndersenKKKjaerSK. Thyroid cancer in Denmark 1943-2008, before and after iodine supplementation. Int J Cancer (2012) 131(10):2360–6.10.1002/ijc.27497

  • 7

    KilfoyBAZhengTHolfordTRHanXWardMHSjodinAet alInternational patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control (2009) 20(5):525–31.10.1007/s10552-008-9260-4

  • 8

    BritoJPDaviesL. Is there really an increased incidence of thyroid cancer?Curr Opin Endocrinol Diabetes Obes (2014) 21(5):405–8.10.1097/MED.0000000000000094

  • 9

    McNallyRJBlakeyKJamesPWGomez PozoBBastaNOHaleJ. Increasing incidence of thyroid cancer in Great Britain, 1976-2005: age-period-cohort analysis. Eur J Epidemiol (2012) 27(8):615–22.10.1007/s10654-012-9710-x

  • 10

    MorrisLGMyssiorekD. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg (2010) 200(4):454–61.10.1016/j.amjsurg.2009.11.008

  • 11

    GschwandtnerEKlatteTSwietekNBuresCKoberFOttJet alIncrease of papillary thyroid microcarcinoma and a plea for restrictive treatment: a retrospective study of 1,391 prospective documented patients. Surgery (2016) 159(2):503–11.10.1016/j.surg.2015.06.015

  • 12

    HayIDHutchinsonMEGonzalez-LosadaTMcIverBReinaldaMEGrantCSet alPapillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery (2008) 144(6):980–7; discussion 987–8.10.1016/j.surg.2008.08.035

  • 13

    ImaizumiMUsaTTominagaTNeriishiKAkahoshiMNakashimaEet alRadiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. JAMA (2006) 295(9):1011–22.10.1001/jama.295.9.1011

  • 14

    Preston-MartinSFranceschiSRonENegriE. Thyroid cancer pooled analysis from 14 case-control studies: what have we learned?Cancer Causes Control (2003) 14(8):787–9.10.1023/A:1026312203045

  • 15

    IribarrenCHaselkornTTekawaISFriedmanGD. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer (2001) 93(5):745–50.10.1002/ijc.1377

  • 16

    LeenhardtLGrosclaudeP. [Epidemiology of thyroid carcinoma over the world]. Ann Endocrinol (Paris) (2011) 72(2):136–48.10.1016/j.ando.2011.03.025

  • 17

    KungTMNgWLGibsonJB. Volcanoes and carcinoma of the thyroid: a possible association. Arch Environ Health (1981) 36(5):265–7.10.1080/00039896.1981.10667635

  • 18

    DuntasLHDoumasC. The ‘rings of fire’ and thyroid cancer. Hormones (Athens) (2009) 8(4):249–53.10.14310/horm.2002.1242

  • 19

    MalandrinoPScolloCMarturanoIRussoMTavarelliMAttardMet alDescriptive epidemiology of human thyroid cancer: experience from a regional registry and the “volcanic factor”. Front Endocrinol (2013) 4:65.10.3389/fendo.2013.00065

  • 20

    MarkakiILinosDLinosA. The influence of dietary patterns on the development of thyroid cancer. Eur J Cancer (2003) 39(13):1912–9.10.1016/S0959-8049(03)00432-5

  • 21

    KitaharaCMPlatzEAFreemanLEHsingAWLinetMSParkYet alObesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev (2011) 20(3):464–72.10.1158/1055-9965.EPI-10-1220

  • 22

    Rego-IraetaAPerez-MendezLFMantinanBGarcia-MayorRV. Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid (2009) 19(4):333–40.10.1089/thy.2008.0210

  • 23

    CalleEEKaaksR. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 4(8):579–91.10.1038/nrc1408

  • 24

    DugganCIrwinMLXiaoLHendersonKDSmithAWBaumgartnerRNet alAssociations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol (2011) 29(1):32–9.10.1200/JCO.2009.26.4473

  • 25

    PathakSPandanaboyanaSDanielsISmartNPrasadKR. Obesity and colorectal liver metastases: mechanisms and management. Surg Oncol (2016) 25(3):246–51.10.1016/j.suronc.2016.05.021

  • 26

    IyengarNMGucalpADannenbergAJHudisCA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol (2016) 34(35):4270–6.10.1200/JCO.2016.67.4283

  • 27

    Dal MasoLLa VecchiaCFranceschiSPreston-MartinSRonELeviFet alA pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control (2000) 11(2):137–44.10.1023/A:1008938520101

  • 28

    SamanicCGridleyGChowWHLubinJHooverRNFraumeniJFJr. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control (2004) 15(1):35–43.10.1023/B:CACO.0000016573.79453.ba

  • 29

    EngelandATretliSAkslenLABjorgeT. Body size and thyroid cancer in two million Norwegian men and women. Br J Cancer (2006) 95(3):366–70.10.1038/sj.bjc.6603249

  • 30

    RappKSchroederJKlenkJStoehrSUlmerHConcinHet alObesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer (2005) 93(9):1062–7.10.1038/sj.bjc.6602819

  • 31

    SamanicCChowWHGridleyGJarvholmBFraumeniJFJr. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control (2006) 17(7):901–9.10.1007/s10552-006-0023-9

  • 32

    RenehanAGTysonMEggerMHellerRFZwahlenM. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 371(9612):569–78.10.1016/S0140-6736(08)60269-X

  • 33

    BrindelPDoyonFRachediFBoissinJLSebbagJShanLet alAnthropometric factors in differentiated thyroid cancer in French Polynesia: a case-control study. Cancer Causes Control (2009) 20(5):581–90.10.1007/s10552-008-9266-y

  • 34

    MijovicTHowJPakdamanMRochonLGologanOHierMPet alBody mass index in the evaluation of thyroid cancer risk. Thyroid (2009) 19(5):467–72.10.1089/thy.2008.0386

  • 35

    CleroELeuxCBrindelPTruongTAngerATeinturierCet alPooled analysis of two case-control studies in New Caledonia and French Polynesia of body mass index and differentiated thyroid cancer: the importance of body surface area. Thyroid (2010) 20(11):1285–93.10.1089/thy.2009.0456

  • 36

    LeitzmannMFBrennerAMooreSCKoebnickCParkYHollenbeckAet alProspective study of body mass index, physical activity and thyroid cancer. Int J Cancer (2010) 126(12):2947–56.10.1002/ijc.24913

  • 37

    MeinholdCLRonESchonfeldSJAlexanderBHFreedmanDMLinetMSet alNonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol (2010) 171(2):242–52.10.1093/aje/kwp354

  • 38

    RezzonicoJNRezzonicoMPusiolEPitoiaFNiepomniszczeH. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord (2009) 7(4):375–80.10.1089/met.2008.0062

  • 39

    BaeMJKimSSKimWJYiYSJeonYKKimBHet alHigh prevalence of papillary thyroid cancer in Korean women with insulin resistance. Head Neck (2016) 38(1):66–71.10.1002/hed.23848

  • 40

    RonEKleinermanRABoiceJDJrLiVolsiVAFlanneryJTFraumeniJFJr. A population-based case-control study of thyroid cancer. J Natl Cancer Inst (1987) 79(1):1–12.

  • 41

    OhSWYoonYSShinSA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol (2005) 23(21):4742–54.10.1200/JCO.2005.11.726

  • 42

    AlmquistMJohansenDBjorgeTUlmerHLindkvistBStocksTet alMetabolic factors and risk of thyroid cancer in the metabolic syndrome and cancer project (Me-Can). Cancer Causes Control (2011) 22(5):743–51.10.1007/s10552-011-9747-2

  • 43

    RinaldiSLiseMClavel-ChapelonFBoutron-RuaultMCGuillasGOvervadKet alBody size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer (2012) 131(6):E1004–14.10.1002/ijc.27601

  • 44

    KimHJKimNKChoiJHSohnSYKimSWJinSMet alAssociations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf) (2013) 78(1):134–40.10.1111/j.1365-2265.2012.04506.x

  • 45

    ObermanBKhakuACamachoFGoldenbergD. Relationship between obesity, diabetes and the risk of thyroid cancer. Am J Otolaryngol (2015) 36(4):535–41.10.1016/j.amjoto.2015.02.015

  • 46

    WideroffLGridleyGMellemkjaerLChowWHLinetMKeehnSet alCancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst (1997) 89(18):1360–5.10.1093/jnci/89.18.1360

  • 47

    ChodickGHeymannADRosenmannLGreenMSFlashSPorathAet alDiabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control (2010) 21(6):879–87.10.1007/s10552-010-9515-8

  • 48

    Aschebrook-KilfoyBSabraMMBrennerAMooreSCRonESchatzkinAet alDiabetes and thyroid cancer risk in the National Institutes of Health-AARP diet and health study. Thyroid (2011) 21(9):957–63.10.1089/thy.2010.0396

  • 49

    DuranAOAnilCGursoyANarAAltundagOTutuncuNB. The relationship between glucose metabolism disorders and malignant thyroid disease. Int J Clin Oncol (2013) 18(4):585–9.10.1007/s10147-012-0435-3

  • 50

    LaiGYParkYHartgePHollenbeckARFreedmanND. The association between self-reported diabetes and cancer incidence in the NIH-AARP diet and health study. J Clin Endocrinol Metab (2013) 98(3):E497–502.10.1210/jc.2012-3335

  • 51

    TsengCH. Diabetes and thyroid cancer mortality: a 12-year prospective follow-up of Taiwanese. Eur J Clin Invest (2013) 43(6):595–601.10.1111/eci.12086

  • 52

    PaulusYMRiedelERSabraMMTuttleRMKalinMF. Prevalence of diabetes mellitus in patients with newly evaluated papillary thyroid cancer. Thyroid Res (2014) 7:7.10.1186/1756-6614-7-7

  • 53

    YeoYMaSHHwangYHorn-RossPLHsingALeeKEet alDiabetes mellitus and risk of thyroid cancer: a meta-analysis. PLoS One (2014) 9(6):e98135.10.1371/journal.pone.0098135

  • 54

    KabatGCKimMYThomsonCALuoJWactawski-WendeJRohanTE. Anthropometric factors and physical activity and risk of thyroid cancer in postmenopausal women. Cancer Causes Control (2012) 23(3):421–30.10.1007/s10552-011-9890-9

  • 55

    KitaharaCMPlatzEAParkYHollenbeckARSchatzkinABerrington de GonzalezA. Body fat distribution, weight change during adulthood, and thyroid cancer risk in the NIH-AARP diet and health study. Int J Cancer (2012) 130(6):1411–9.10.1002/ijc.26161

  • 56

    KitaharaCMMcCulloughMLFranceschiSRinaldiSWolkANetaGet alAnthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid (2016) 26(2):306–18.10.1089/thy.2015.0319

  • 57

    ZhaoZGGuoXGBaCXWangWYangYYWangJet alOverweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J Int Med Res (2012) 40(6):2041–50.10.1177/030006051204000601

  • 58

    TresalletCSemanMTissierFBuffetCLupinacciRMVuarnessonHet alThe incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices. Surgery (2014) 156(5):1145–52.10.1016/j.surg.2014.04.020

  • 59

    HarariAEndoBNishimotoSItuartePHYehMW. Risk of advanced papillary thyroid cancer in obese patients. Arch Surg (2012) 147(9):805–11.10.1001/archsurg.2012.713

  • 60

    PaesJEHuaKNagyRKloosRTJarjouraDRingelMD. The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab (2010) 95(9):4244–50.10.1210/jc.2010-0440

  • 61

    Paz-FilhoGLimELWongMLLicinioJ. Associations between adipokines and obesity-related cancer. Front Biosci (2011) 16:1634–50.10.2741/3810

  • 62

    ChengSPYinPHChangYCLeeCHHuangSYChiCW. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep (2010) 23(6):1721–7.10.3892/or_00000817

  • 63

    UddinSHussainARSirajAKKhanOSBaviPPAl-KurayaKS. Role of leptin and its receptors in the pathogenesis of thyroid cancer. Int J Clin Exp Pathol (2011) 4(7):637–43.

  • 64

    Pazaitou-PanayiotouKPolyzosSAMantzorosCS. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes Rev (2013) 14(12):1006–22.10.1111/obr.12070

  • 65

    MitsiadesNPazaitou-PanayiotouKAronisKNMoonHSChamberlandJPLiuXet alCirculating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab (2011) 96(12):E2023–8.10.1210/jc.2010-1908

  • 66

    HsiehCJWangPWWangSTLiuRTTungSCChienWYet alSerum leptin concentrations of patients with sequential thyroid function changes. Clin Endocrinol (Oxf) (2002) 57(1):29–34.10.1046/j.1365-2265.2002.01543.x

  • 67

    AkinciMKosovaFCetinBAslanSAriZCetinA. Leptin levels in thyroid cancer. Asian J Surg (2009) 32(4):216–23.10.1016/S1015-9584(09)60397-3

  • 68

    HedayatiMYaghmaeiPPooyamaneshZZarif YeganehMHoghooghi RadL. Leptin: a correlated peptide to papillary thyroid carcinoma?J Thyroid Res (2011) 2011:832163.10.4061/2011/832163

  • 69

    ChengSPChiCWTzenCYYangTLLeeJJLiuTPet alClinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery (2010) 147(6):847–53.10.1016/j.surg.2009.11.004

  • 70

    LinSYHuangSCSheuWH. Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal. Metabolism (2010) 59(2):195–9.10.1016/j.metabol.2009.06.032

  • 71

    ParkJTYooTHChangTILeeDHLeeJHLeeJEet alInsulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients. Metabolism (2011) 60(1):121–6.10.1016/j.metabol.2010.02.006

  • 72

    ChengSPLiuCLHsuYCChangYCHuangSYLeeJJ. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys (2013) 65(2):203–10.10.1007/s12013-012-9419-1

  • 73

    ChamSZanoccoKSturgeonCYehMWHarariA. Risk-based ultrasound screening for thyroid cancer in obese patients is cost-effective. Thyroid (2014) 24(6):975–86.10.1089/thy.2013.0470

  • 74

    KimuraTVan KeymeulenAGolsteinJFuscoADumontJERogerPP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev (2001) 22(5):631–56.10.1210/edrv.22.5.0444

  • 75

    BoelaertKHoracekJHolderRLWatkinsonJCSheppardMCFranklynJA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab (2006) 91(11):4295–301.10.1210/jc.2006-0527

  • 76

    HaymartMRRepplingerDJLeversonGEElsonDFSippelRSJaumeJCet alHigher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab (2008) 93(3):809–14.10.1210/jc.2007-2215

  • 77

    FioreERagoTProvenzaleMAScutariMUgoliniCBasoloFet alLower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer (2009) 16(4):1251–60.10.1677/ERC-09-0036

  • 78

    TramontanoDCushingGWMosesACIngbarSH. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. Endocrinology (1986) 119(2):940–2.10.1210/endo-119-2-940

  • 79

    KanamoriAAbeYYajimaYManabeYItoK. Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands. J Clin Endocrinol Metab (1989) 68(5):899–903.10.1210/jcem-68-5-899

  • 80

    HaugenDRAkslenLAVarhaugJELillehaugJR. Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer (1992) 65(6):832–7.10.1038/bjc.1992.177

  • 81

    BelfioreAGangemiPCostantinoARussoGSantonocitoGMIppolitoOet alNegative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab (1997) 82(7):2322–8.10.1210/jcem.82.7.4104

  • 82

    EggoMCHopkinsJMFranklynJAJohnsonGDSandersDSSheppardMC. Expression of fibroblast growth factors in thyroid cancer. J Clin Endocrinol Metab (1995) 80(3):1006–11.10.1210/jcem.80.3.7533768

  • 83

    MilazzoGLa RosaGLCatalfamoRVigneriRBelfioreA. Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects. J Cell Biochem (1992) 49(3):231–8.10.1002/jcb.240490305

  • 84

    MariansRCNgLBlairHCUngerPGravesPNDaviesTF. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc Natl Acad Sci U S A (2002) 99(24):15776–81.10.1073/pnas.242322099

  • 85

    Garcia-JimenezCSantistebanP. TSH signalling and cancer. Arq Bras Endocrinol Metabol (2007) 51(5):654–71.10.1590/S0004-27302007000500003

  • 86

    De FeliceMPostiglioneMPDi LauroR. Minireview: thyrotropin receptor signaling in development and differentiation of the thyroid gland: insights from mouse models and human diseases. Endocrinology (2004) 145(9):4062–7.10.1210/en.2004-0501

  • 87

    RichardsJS. New signaling pathways for hormones and cyclic adenosine 3’,5’-monophosphate action in endocrine cells. Mol Endocrinol (2001) 15(2):209–18.10.1210/mend.15.2.0606

  • 88

    FrascaFVellaVNicolosiMLMessinaRLGianiFLottaSet alThyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. J Clin Endocrinol Metab (2013) 98(6):2502–12.10.1210/jc.2012-3623

  • 89

    MedinaDLSuzukiKPietrarelliMOkajimaFKohnLDSantistebanP. Role of insulin and serum on thyrotropin regulation of thyroid transcription factor-1 and pax-8 genes expression in FRTL-5 thyroid cells. Thyroid (2000) 10(4):295–303.10.1089/thy.2000.10.295

  • 90

    MalaguarneraRFrascaFGarozzoAGianiFPandiniGVellaVet alInsulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab (2011) 96(3):766–74.10.1210/jc.2010-1255

  • 91

    DumontJELamyFRogerPMaenhautC. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev (1992) 72(3):667–97.

  • 92

    RiedemannJMacaulayVM. IGF1R signalling and its inhibition. Endocr Relat Cancer (2006) 13(Suppl 1):S33–43.10.1677/erc.1.01280

  • 93

    MohanSBaylinkDJPettisJL. Insulin-like growth factor (IGF)-binding proteins in serum – do they have additional roles besides modulating the endocrine IGF actions?J Clin Endocrinol Metab (1996) 81(11):3817–20.10.1210/jcem.81.11.8923818

  • 94

    SantistebanPAcebronAPolycarpou-SchwarzMDi LauroR. Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter. Mol Endocrinol (1992) 6(8):1310–7.10.1210/mend.6.8.1406708

  • 95

    OrtizLZanniniMDi LauroRSantistebanP. Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin, and insulin-like growth factor I. J Biol Chem (1997) 272(37):23334–9.10.1074/jbc.272.37.23334

  • 96

    VellaVSciaccaLPandiniGMineoRSquatritoSVigneriRet alThe IGF system in thyroid cancer: new concepts. Mol Pathol (2001) 54(3):121–4.10.1136/mp.54.3.121

  • 97

    VellaVPandiniGSciaccaLMineoRVigneriRPezzinoVet alA novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab (2002) 87(1):245–54.10.1210/jcem.87.1.8142

  • 98

    CondorelliGFormisanoPMieleCBeguinotF. Thyrotropin regulates autophosphorylation and kinase activity in both the insulin and the insulin-like growth factor-I receptors in FRTL5 cells. Endocrinology (1992) 130(3):1615–25.10.1210/endo.130.3.1311244

  • 99

    FrascaFPandiniGScaliaPSciaccaLMineoRCostantinoAet alInsulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 19(5):3278–88.10.1128/MCB.19.5.3278

  • 100

    SciaccaLCostantinoAPandiniGMineoRFrascaFScaliaPet alInsulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene (1999) 18(15):2471–9.10.1038/sj.onc.1202600

  • 101

    BelfioreAMalaguarneraR. Insulin receptor and cancer. Endocr Relat Cancer (2011) 18(4):R125–47.10.1530/ERC-11-0074

  • 102

    PandiniGVigneriRCostantinoAFrascaFIppolitoAFujita-YamaguchiYet alInsulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res (1999) 5(7):1935–44.

  • 103

    PapaVGliozzoBClarkGMMcGuireWLMooreDFujita-YamaguchiYet alInsulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res (1993) 53(16):3736–40.

  • 104

    KodaMSulkowskiSGarofaloCKanczuga-KodaLSulkowskaMSurmaczE. Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors alpha and beta. Horm Metab Res (2003) 35(11–12):794–801.10.1055/s-2004-814152

  • 105

    MalaguarneraRBelfioreA. The insulin receptor: a new target for cancer therapy. Front Endocrinol (2011) 2:93.10.3389/fendo.2011.00093

  • 106

    ChakravartyGSantillanAAGalerCAdamsHPEl-NaggarAKJasserSAet alPhosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer. Exp Biol Med (Maywood) (2009) 234(4):372–86.10.3181/0809-RM-284

  • 107

    YanYHuFWuWMaRHuangH. Expression characteristics of proteins of IGF-1R, p-Akt, and survivin in papillary thyroid carcinoma patients with type 2 diabetes mellitus. Medicine (Baltimore) (2017) 96(12):e6393.10.1097/MD.0000000000006393

  • 108

    GianiFVellaVNicolosiMLFierabracciALottaSMalaguarneraRet alThyrospheres from normal or malignant thyroid tissue have different biological, functional, and genetic features. J Clin Endocrinol Metab (2015) 100(9):E1168–78.10.1210/JC.2014-4163

  • 109

    BiondiB. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab (2010) 95(8):3614–7.10.1210/jc.2010-1245

  • 110

    NevesJSCastro OliveiraSSouteiroPPedroJMagalhaesDGuerreiroVet alEffect of weight loss after bariatric surgery on thyroid-stimulating hormone levels in patients with morbid obesity and normal thyroid function. Obes Surg (2017).10.1007/s11695-017-2792-5

  • 111

    IacobellisGRibaudoMCZappaterrenoAIannucciCVLeonettiF. Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. Clin Endocrinol (Oxf) (2005) 62(4):487–91.10.1111/j.1365-2265.2005.02247.x

  • 112

    RadettiGKleonWBuziFCrivellaroCPappalardoLdi IorgiNet alThyroid function and structure are affected in childhood obesity. J Clin Endocrinol Metab (2008) 93(12):4749–54.10.1210/jc.2008-0823

  • 113

    SariRBalciMKAltunbasHKarayalcinU. The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol (Oxf) (2003) 59(2):258–62.10.1046/j.1365-2265.2003.01836.x

  • 114

    ReinehrTAndlerW. Thyroid hormones before and after weight loss in obesity. Arch Dis Child (2002) 87(4):320–3.10.1136/adc.87.4.320

  • 115

    ReinehrTIsaAde SousaGDieffenbachRAndlerW. Thyroid hormones and their relation to weight status. Horm Res (2008) 70(1):51–7.10.1159/000129678

  • 116

    MichalakiMAVagenakisAGLeonardouASArgentouMNHabeosIGMakriMGet alThyroid function in humans with morbid obesity. Thyroid (2006) 16(1):73–8.10.1089/thy.2006.16.73

  • 117

    JayanthiRSrinivasanARHanifahMMaranAL. Associations among insulin resistance, triacylglycerol/high density lipoprotein (TAG/HDL ratio) and thyroid hormone levels – a study on type 2 diabetes mellitus in obese and overweight subjects. Diabetes Metab Syndr (2016).10.1016/j.dsx.2016.12.020

  • 118

    NillniEAVasletCHarrisMHollenbergABjorbakCFlierJS. Leptin regulates prothyrotropin-releasing hormone biosynthesis. Evidence for direct and indirect pathways. J Biol Chem (2000) 275(46):36124–33.10.1074/jbc.M003549200

  • 119

    BurmanKDSmallridgeRCOsburneRDimondRCWhortonNEKeslerPet alNature of suppressed TSH secretion during undernutrition: effect of fasting and refeeding on TSH responses to prolonged TRH infusions. Metabolism (1980) 29(1):46–52.10.1016/0026-0495(80)90097-9

  • 120

    HarrisMAschkenasiCEliasCFChandrankunnelANillniEABjoorbaekCet alTranscriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling. J Clin Invest (2001) 107(1):111–20.10.1172/JCI10741

  • 121

    CiavardelliDBellomoMCrescimannoCVellaV. Type 3 deiodinase: role in cancer growth, stemness, and metabolism. Front Endocrinol (2014) 5:215.10.3389/fendo.2014.00215

  • 122

    FontenelleLCFeitosaMMSeveroJSFreitasTEMoraisJBTorres-LealFLet alThyroid function in human obesity: underlying mechanisms. Horm Metab Res (2016) 48(12):787–94.10.1055/s-0042-121421

  • 123

    MuellerASchoflCDittrichRCupistiSOppeltPGSchildRLet alThyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. Hum Reprod (2009) 24(11):2924–30.10.1093/humrep/dep285

  • 124

    Benetti-PintoCLPiccoloVBYelaDAGarmesH. Thyroid-stimulating hormone and insulin resistance: their association with polycystic ovary syndrome without overt hypothyroidism. Rev Bras Ginecol Obstet (2017) 39(5):224–8.10.1055/s-0037-1601436

  • 125

    TrummerCSchwetzVGiulianiAObermayer-PietschBLerchbaumE. Impact of elevated thyroid-stimulating hormone levels in polycystic ovary syndrome. Gynecol Endocrinol (2015) 31(10):819–23.10.3109/09513590.2015.1062864

  • 126

    YinDRuanXTianXDuJZhaoYCuiYet alThe relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome. Gynecol Endocrinol (2017) 33(4):332–5.10.1080/09513590.2016.1273895

  • 127

    SinhaUSinharayKSahaSLongkumerTABaulSNPalSK. Thyroid disorders in polycystic ovarian syndrome subjects: a tertiary hospital based cross-sectional study from Eastern India. Indian J Endocrinol Metab (2013) 17(2):304–9.10.4103/2230-8210.109714

  • 128

    JayanthiRSrinivasanARGopalNRamaswamyR. Association of divalent cations and insulin resistance with thyroid hormones in patients with type 2 diabetes mellitus. Diabetes Metab Syndr (2017).10.1016/j.dsx.2017.07.010

  • 129

    WolideADZawdieBAlemayehuTTadesseS. Association between thyroid hormone parameters and dyslipidemia among type 2 diabetes mellitus patients: comparative cross-sectional study. Diabetes Metab Syndr (2016).10.1016/j.dsx.2016.12.041

  • 130

    TaneichiHSasaiTOharaMHonmaHNagasawaKTakahashiTet alHigher serum free triiodothyronine levels within the normal range are associated with metabolic syndrome components in type 2 diabetic subjects with euthyroidism. Tohoku J Exp Med (2011) 224(3):173–8.10.1620/tjem.224.173

  • 131

    LaiYWangJJiangFWangBChenYLiMet alThe relationship between serum thyrotropin and components of metabolic syndrome. Endocr J (2011) 58(1):23–30.10.1507/endocrj.K10E-272

  • 132

    RoosABakkerSJLinksTPGansROWolffenbuttelBH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab (2007) 92(2):491–6.10.1210/jc.2006-1718

  • 133

    SieminskaLWojciechowskaCWalczakKBorowskiAMarekBNowakMet alAssociations between metabolic syndrome, serum thyrotropin, and thyroid antibodies status in postmenopausal women, and the role of interleukin-6. Endokrynol Pol (2015) 66(5):394–403.10.5603/EP.2015.0049

  • 134

    MehranLAmouzegarATohidiMMoayediMAziziF. Serum free thyroxine concentration is associated with metabolic syndrome in euthyroid subjects. Thyroid (2014) 24(11):1566–74.10.1089/thy.2014.0103

  • 135

    Benetti-PintoCLBerini PiccoloVRGarmesHMTeatin JuliatoCR. Subclinical hypothyroidism in young women with polycystic ovary syndrome: an analysis of clinical, hormonal, and metabolic parameters. Fertil Steril (2013) 99(2):588–92.10.1016/j.fertnstert.2012.10.006

  • 136

    LecubeAZafonCGromazAFortJMCaubetEBaenaJAet alIodine deficiency is higher in morbid obesity in comparison with late after bariatric surgery and non-obese women. Obes Surg (2015) 25(1):85–9.10.1007/s11695-014-1313-z

  • 137

    SoriguerFValdesSMorcilloSEstevaIAlmarazMCde AdanaMSet alThyroid hormone levels predict the change in body weight: a prospective study. Eur J Clin Invest (2011) 41(11):1202–9.10.1111/j.1365-2362.2011.02526.x

  • 138

    ErayESariFOzdemSSariR. Relationship between thyroid volume and iodine, leptin, and adiponectin in obese women before and after weight loss. Med Princ Pract (2011) 20(1):43–6.10.1159/000322075

  • 139

    Al-AttasOSAl-DaghriNMAlkharfyKMAlokailMSAl-JohaniNJAbd-AlrahmanSHet alUrinary iodine is associated with insulin resistance in subjects with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes (2012) 120(10):618–22.10.1055/s-0032-1323816

  • 140

    RundleAHoepnerLHassounAOberfieldSFreyerGHolmesDet alAssociation of childhood obesity with maternal exposure to ambient air polycyclic aromatic hydrocarbons during pregnancy. Am J Epidemiol (2012) 175(11):1163–72.10.1093/aje/kwr455

  • 141

    FierensSMairesseHHeilierJFDe BurbureCFocantJFEppeGet alDioxin/polychlorinated biphenyl body burden, diabetes and endometriosis: findings in a population-based study in Belgium. Biomarkers (2003) 8(6):529–34.10.1080/1354750032000158420

  • 142

    LimJSLeeDHJacobsDRJr. Association of brominated flame retardants with diabetes and metabolic syndrome in the U.S. population, 2003-2004. Diabetes Care (2008) 31(9):1802–7.10.2337/dc08-0850

  • 143

    LeeDHLeeIKSongKSteffesMToscanoWBakerBAet alA strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care (2006) 29(7):1638–44.10.2337/dc06-0543

  • 144

    WolfKPoppASchneiderABreitnerSHampelRRathmannWet alAssociation between long-term exposure to air pollution and biomarkers related to insulin resistance, subclinical inflammation, and adipokines. Diabetes (2016) 65(11):3314–26.10.2337/db15-1567

  • 145

    HenriksenGLKetchumNSMichalekJESwabyJA. Serum dioxin and diabetes mellitus in veterans of Operation Ranch Hand. Epidemiology (1997) 8(3):252–8.10.1097/00001648-199705000-00005

  • 146

    LeeDHLindPMJacobsDRJrSalihovicSvan BavelBLindL. Polychlorinated biphenyls and organochlorine pesticides in plasma predict development of type 2 diabetes in the elderly: the prospective investigation of the vasculature in uppsala seniors (PIVUS) study. Diabetes Care (2011) 34(8):1778–84.10.2337/dc10-2116

  • 147

    KramerUHerderCSugiriDStrassburgerKSchikowskiTRanftUet alTraffic-related air pollution and incident type 2 diabetes: results from the SALIA cohort study. Environ Health Perspect (2010) 118(9):1273–9.10.1289/ehp.0901689

  • 148

    WeinmayrGHennigFFuksKNonnemacherMJakobsHMohlenkampSet alLong-term exposure to fine particulate matter and incidence of type 2 diabetes mellitus in a cohort study: effects of total and traffic-specific air pollution. Environ Health (2015) 14:53.10.1186/s12940-015-0031-x

  • 149

    JerrettMBrookRWhiteLFBurnettRTYuJSuJet alAmbient ozone and incident diabetes: a prospective analysis in a large cohort of African American women. Environ Int (2017) 102:42–7.10.1016/j.envint.2016.12.011

  • 150

    CooganPFWhiteLFJerrettMBrookRDSuJGSetoEet alAir pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles. Circulation (2012) 125(6):767–72.10.1161/CIRCULATIONAHA.111.052753

  • 151

    LangIAGallowayTSScarlettAHenleyWEDepledgeMWallaceRBet alAssociation of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA (2008) 300(11):1303–10.10.1001/jama.300.11.1303

  • 152

    LeeDHLeeIKJinSHSteffesMJacobsDRJr. Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetes Care (2007) 30(3):622–8.10.2337/dc06-2190

  • 153

    LeeDHLeeIKPortaMSteffesMJacobsDRJr. Relationship between serum concentrations of persistent organic pollutants and the prevalence of metabolic syndrome among non-diabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetologia (2007) 50(9):1841–51.10.1007/s00125-007-0755-4

  • 154

    KandarakiEChatzigeorgiouALivadasSPaliouraEEconomouFKoutsilierisMet alEndocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab (2011) 96(3):E480–4.10.1210/jc.2010-1658

  • 155

    AkinLKendirciMNarinFKurtogluSSaraymenRKondolotMet alThe endocrine disruptor bisphenol A may play a role in the aetiopathogenesis of polycystic ovary syndrome in adolescent girls. Acta Paediatr (2015) 104(4):e171–7.10.1111/apa.12885

  • 156

    TarantinoGValentinoRDi SommaCD’EspositoVPassarettiFPizzaGet alBisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin Endocrinol (Oxf) (2013) 78(3):447–53.10.1111/j.1365-2265.2012.04500.x

  • 157

    RajkhowaMBicknellJJonesMClaytonRN. Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril (1994) 61(4):605–12.10.1016/S0015-0282(16)56633-3

  • 158

    TakeuchiTTsutsumiO. Serum bisphenol A concentrations showed gender differences, possibly linked to androgen levels. Biochem Biophys Res Commun (2002) 291(1):76–8.10.1006/bbrc.2002.6407

  • 159

    TakeuchiTTsutsumiOIkezukiYTakaiYTaketaniY. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J (2004) 51(2):165–9.10.1507/endocrj.51.165

  • 160

    MiaoMYuanWYangFLiangHZhouZLiRet alAssociations between bisphenol A exposure and reproductive hormones among female workers. Int J Environ Res Public Health (2015) 12(10):13240–50.10.3390/ijerph121013240

  • 161

    RotondiMLeporatiPLa MannaAPiraliBMondelloTFonteRet alRaised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism?Eur J Endocrinol (2009) 160(3):403–8.10.1530/EJE-08-0734

  • 162

    AkbarDHAhmedMMAl-MughalesJ. Thyroid dysfunction and thyroid autoimmunity in Saudi type 2 diabetics. Acta Diabetol (2006) 43(1):14–8.10.1007/s00592-006-0204-8

  • 163

    YasminTGhafoorFMalikTRuhy NazSKhanAU. Pattern of thyroid autoimmunity in type 1 and type 2 diabetics. J Coll Physicians Surg Pak (2006) 16(12):751–4. doi: 12.2006/JCPSP.751754

  • 164

    ToulisKTsekmekidouXPotolidisEDidangelosTGotzamani-PsarrakouAZebekakisPet alThyroid autoimmunity in the context of type 2 diabetes mellitus: implications for vitamin D. Int J Endocrinol (2015) 2015:710363.10.1155/2015/710363

  • 165

    Sarfo-KantankaOSarfoFSAnsahEOYorkeEAkpaluJNkumBCet alFrequency and determinants of thyroid autoimmunity in Ghanaian type 2 diabetes patients: a case-control study. BMC Endocr Disord (2017) 17(1):2.10.1186/s12902-016-0152-4

  • 166

    Al-SaabRHaddadS. Detection of thyroid autoimmunity markers in euthyroid women with polycystic ovary syndrome: a case-control study from Syria. Int J Endocrinol Metab (2014) 12(3):e17954.10.5812/ijem.17954

  • 167

    JanssenOEMehlmauerNHahnSOffnerAHGartnerR. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol (2004) 150(3):363–9.10.1530/eje.0.1500363

  • 168

    MenonMRamachandranV. Antithyroid peroxidase antibodies in women with polycystic ovary syndrome. J Obstet Gynaecol India (2017) 67(1):61–5.10.1007/s13224-016-0914-y

  • 169

    GarelliSMasieroSPlebaniMChenSFurmaniakJArmaniniDet alHigh prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol (2013) 169(2):248–51.10.1016/j.ejogrb.2013.03.003

  • 170

    KachueiMJafariFKachueiAKeshteliAH. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Arch Gynecol Obstet (2012) 285(3):853–6.10.1007/s00404-011-2040-5

  • 171

    Novais JdeSBenetti-PintoCLGarmesHMJalesRMJuliatoCR. Polycystic ovary syndrome and chronic autoimmune thyroiditis. Gynecol Endocrinol (2015) 31(1):48–51.10.3109/09513590.2014.958990

  • 172

    ArducAAycicek DoganBBilmezSImga NasirogluNTunaMMIsikSet alHigh prevalence of Hashimoto’s thyroiditis in patients with polycystic ovary syndrome: does the imbalance between estradiol and progesterone play a role?Endocr Res (2015) 40(4):204–10.10.3109/07435800.2015.1015730

  • 173

    GanieMAMarwahaRKAggarwalRSinghS. High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case-control study. Eur J Endocrinol (2010) 162(6):1117–22.10.1530/EJE-09-1012

  • 174

    WangKYangYWuYChenJZhangDMaoXet alThe association between insulin resistance and vascularization of thyroid nodules. J Clin Endocrinol Metab (2015) 100(1):184–92.10.1210/jc.2014-2723

  • 175

    GallagherEJLeRoithD. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev (2015) 95(3):727–48.10.1152/physrev.00030.2014

  • 176

    Ben-ShmuelSRostokerRScheinmanEJLeRoithD. Metabolic syndrome, type 2 diabetes, and cancer: epidemiology and potential mechanisms. Handb Exp Pharmacol (2016) 233:355–72.10.1007/164_2015_12

  • 177

    RostokerRAbelsonSBitton-WormsKGenkinIBen-ShmuelSDakwarMet alHighly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer (2015) 22(2):145–57.10.1530/ERC-14-0490

  • 178

    ZelenkoZGallagherEJAntoniouIMSachdevDNayakAYeeDet alEMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice. Endocr Relat Cancer (2016) 23(9):747–58.10.1530/ERC-16-0142

  • 179

    GallagherEJAlikhaniNTobin-HessABlankJBuffinNJZelenkoZet alInsulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes (2013) 62(10):3553–60.10.2337/db13-0249

  • 180

    MalaguarneraRNicolosiMLSaccoAMorcavalloAVellaVVociCet alNovel cross talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses. Oncotarget (2015) 6(18):16084–105.10.18632/oncotarget.3177

  • 181

    VellaVMalaguarneraRNicolosiMLPalladinoCSpoletiCMassiminoMet alDiscoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells. Oncotarget (2017) 8(26):43248–70.10.18632/oncotarget.18020

  • 182

    De MarcoPRomeoEVivacquaAMalaguarneraRAbonanteSRomeoFet alGPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocr Relat Cancer (2014) 21(5):739–53.10.1530/ERC-14-0245

  • 183

    MataRPalladinoCNicolosiMLLo PrestiARMalaguarneraRRagusaMet alIGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget (2016) 7(7):7683–700.10.18632/oncotarget.6524

  • 184

    MieleCRochfordJJFilippaNGiorgetti-PeraldiSVan ObberghenE. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem (2000) 275(28):21695–702.10.1074/jbc.M000805200

  • 185

    RoseDPVona-DavisL. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer (2012) 19(6):R225–41.10.1530/ERC-12-0203

  • 186

    ZimmermannMBGalettiV. Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies. Thyroid Res (2015) 8:8.10.1186/s13044-015-0020-8

  • 187

    ZimmermannMBBoelaertK. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol (2015) 3(4):286–95.10.1016/S2213-8587(14)70225-6

  • 188

    LindPLangstegerWMolnarMGallowitschHJMikoschPGomezI. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid (1998) 8(12):1179–83.10.1089/thy.1998.8.1179

  • 189

    BesicNHocevarMZgajnarJ. Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia. Thyroid (2010) 20(6):623–6.10.1089/thy.2009.0404

  • 190

    PellegritiGFrascaFRegalbutoCSquatritoSVigneriR. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol (2013) 2013:965212.10.1155/2013/965212

  • 191

    KrohnKMaierJPaschkeR. Mechanisms of disease: hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors. Nat Clin Pract Endocrinol Metab (2007) 3(10):713–20.10.1038/ncpendmet0621

  • 192

    GerardACHumbletKWilversCPoncinSDerradjiHde Ville de GoyetCet alIodine-deficiency-induced long lasting angiogenic reaction in thyroid cancers occurs via a vascular endothelial growth factor-hypoxia inducible factor-1-dependent, but not a reactive oxygen species-dependent, pathway. Thyroid (2012) 22(7):699–708.10.1089/thy.2011.0387

  • 193

    CrapsJJorisVDe JonghBSonveauxPHormanSLengeleBet alInvolvement of mTOR and regulation by AMPK in early iodine deficiency-induced thyroid microvascular activation. Endocrinology (2016) 157(6):2545–59.10.1210/en.2015-1911

  • 194

    SkrypnykNV. [Correlation between adipocytokines with iodine deficiency criteria in patients with metabolic syndrome and type 2 diabetes mellitus in Carpathians region]. Lik Sprava (2010) (1–2):70–7.

  • 195

    MansourianAR. A review on the metabolic disorders of iodine deficiency. Pak J Biol Sci (2011) 14(7):412–24.10.3923/pjbs.2011.412.424

  • 196

    BoelaertKSyedAAManjiNSheppardMCHolderRLGoughSCet alPrediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf) (2009) 70(1):129–38.10.1111/j.1365-2265.2008.03291.x

  • 197

    PellegritiGDe VathaireFScolloCAttardMGiordanoCArenaSet alPapillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst (2009) 101(22):1575–83.10.1093/jnci/djp354

  • 198

    ArnbjornssonEArnbjornssonAOlafssonA. Thyroid cancer incidence in relation to volcanic activity. Arch Environ Health (1986) 41(1):36–40.10.1080/00039896.1986.9935763

  • 199

    Alonso-MagdalenaPQuesadaINadalA. Endocrine disruptors in the etiology of type 2 diabetes mellitus. Nat Rev Endocrinol (2011) 7(6):346–53.10.1038/nrendo.2011.56

  • 200

    SwedenborgERueggJMakelaSPongratzI. Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders. J Mol Endocrinol (2009) 43(1):1–10.10.1677/JME-08-0132

  • 201

    Casals-CasasCDesvergneB. Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol (2011) 73:135–62.10.1146/annurev-physiol-012110-142200

  • 202

    HolmesD. Endocrine disruptors: air pollution linked to insulin resistance. Nat Rev Endocrinol (2016) 12(12):688.10.1038/nrendo.2016.168

  • 203

    LanzinoMMorelliCGarofaloCPannoMLMauroLAndoSet alInteraction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets (2008) 8(7):597–610.10.2174/156800908786241104

  • 204

    Diamanti-KandarakisEBourguignonJPGiudiceLCHauserRPrinsGSSotoAMet alEndocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev (2009) 30(4):293–342.10.1210/er.2009-0002

  • 205

    HendersonBERossRKPikeMCCasagrandeJT. Endogenous hormones as a major factor in human cancer. Cancer Res (1982) 42(8):3232–9.

  • 206

    DerwahlMNiculaD. Estrogen and its role in thyroid cancer. Endocr Relat Cancer (2014) 21(5):T273–83.10.1530/ERC-14-0053

  • 207

    HuffMOToddSLSmithALElpersJTSmithAPMurphyRDet alArsenite and cadmium activate MAPK/ERK via membrane estrogen receptors and G-protein coupled estrogen receptor signaling in human lung adenocarcinoma cells. Toxicol Sci (2016) 152(1):62–71.10.1093/toxsci/kfw064

  • 208

    LiuZYuXShaikhZA. Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium. Toxicol Appl Pharmacol (2008) 228(3):286–94.10.1016/j.taap.2007.12.017

  • 209

    Di DonatoMCerneraGGiovannelliPGalassoGBilancioAMigliaccioAet alRecent advances on bisphenol-A and endocrine disruptor effects on human prostate cancer. Mol Cell Endocrinol (2017) 457:35–42.10.1016/j.mce.2017.02.045

  • 210

    VinasRWatsonCS. Bisphenol S disrupts estradiol-induced nongenomic signaling in a rat pituitary cell line: effects on cell functions. Environ Health Perspect (2013) 121(3):352–8.10.1289/ehp.1205826

  • 211

    GenuaMPandiniGSisciDCastoriaGMaggioliniMVigneriRet alRole of cyclic AMP response element-binding protein in insulin-like growth factor-I receptor up-regulation by sex steroids in prostate cancer cells. Cancer Res (2009) 69(18):7270–7.10.1158/0008-5472.CAN-09-0088

  • 212

    Feldt-RasmussenURasmussenAK. Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones (Athens) (2010) 9(2):109–17.10.14310/horm.2002.1261

  • 213

    SinghBShahaARTrivediHCarewJFPoluriAShahJP. Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery (1999) 126(6):1070–6; discussion 1076–7.10.1067/msy.2099.101431

  • 214

    JankovicBLeKTHershmanJM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation?J Clin Endocrinol Metab (2013) 98(2):474–82.10.1210/jc.2012-2978

  • 215

    AnandASinghKRKushwahaJKHussainNSonkarAA. Papillary thyroid cancer and Hashimoto’s thyroiditis: an association less understood. Indian J Surg Oncol (2014) 5(3):199–204.10.1007/s13193-014-0325-4

  • 216

    EhlersMSchottM. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked?Trends Endocrinol Metab (2014) 25(12):656–64.10.1016/j.tem.2014.09.001

  • 217

    MarzulloPMinocciATagliaferriMAGuzzaloniGDi BlasioADe MediciCet alInvestigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants. J Clin Endocrinol Metab (2010) 95(8):3965–72.10.1210/jc.2009-2798

  • 218

    VigneriPFrascaFSciaccaLPandiniGVigneriR. Diabetes and cancer. Endocr Relat Cancer (2009) 16(4):1103–23.10.1677/ERC-09-0087

  • 219

    PolyzosSAKitaMEfstathiadouZPoulakosPSlavakisASofianouDet alSerum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol (2008) 134(9):953–60.10.1007/s00432-008-0373-7

  • 220

    JunikRKozinskiMDebska-KozinskaK. Thyroid ultrasound in diabetic patients without overt thyroid disease. Acta Radiol (2006) 47(7):687–91.10.1080/02841850600806308

  • 221

    PimentaWPMazetoGMCallegaroCFShibataSAMarinsLVYamashitaSet al[Thyroid disorders in diabetic patients]. Arq Bras Endocrinol Metabol (2005) 49(2):234–40.10.1590/S0004-27302005000200009

  • 222

    DuranAOAnilCGursoyANarAInancMBozkurtOet alThyroid volume in patients with glucose metabolism disorders. Arq Bras Endocrinol Metabol (2014) 58(8):824–7.10.1590/0004-2730000003418

  • 223

    BlancEPonceCBrodschiDNepoteABarretoASchnitmanMet alAssociation between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome. Metab Syndr Relat Disord (2015) 13(5):221–6.10.1089/met.2014.0158

  • 224

    AnilCAkkurtAAyturkSKutAGursoyA. Impaired glucose metabolism is a risk factor for increased thyroid volume and nodule prevalence in a mild-to-moderate iodine deficient area. Metabolism (2013) 62(7):970–5.10.1016/j.metabol.2013.01.009

  • 225

    AhluwaliaIBMackKAMurphyWMokdadAHBalesVS. State-specific prevalence of selected chronic disease-related characteristics – behavioral risk factor surveillance system, 2001. MMWR Surveill Summ (2003) 52(8):1–80.

  • 226

    JohnsonJABowkerSLRichardsonKMarraCA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia (2011) 54(9):2263–71.10.1007/s00125-011-2242-1

  • 227

    AdamiHOMcLaughlinJEkbomABerneCSilvermanDHackerDet alCancer risk in patients with diabetes mellitus. Cancer Causes Control (1991) 2(5):307–14.10.1007/BF00051670

  • 228

    HemminkiKLiXSundquistJSundquistK. Risk of cancer following hospitalization for type 2 diabetes. Oncologist (2010) 15(6):548–55.10.1634/theoncologist.2009-0300

  • 229

    StocksTBorenaWStrohmaierSBjorgeTManjerJEngelandAet alCohort profile: the metabolic syndrome and cancer project (Me-Can). Int J Epidemiol (2010) 39(3):660–7.10.1093/ije/dyp186

  • 230

    La VecchiaCNegriEFranceschiSD’AvanzoBBoyleP. A case-control study of diabetes mellitus and cancer risk. Br J Cancer (1994) 70(5):950–3.10.1038/bjc.1994.427

  • 231

    ZhanYSFengLTangSHLiWGXuMLiuTFet alGlucose metabolism disorders in cancer patients in a Chinese population. Med Oncol (2010) 27(2):177–84.10.1007/s12032-009-9189-9

  • 232

    KurikiKHiroseKTajimaK. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev (2007) 16(1):83–9.10.1097/01.cej.0000228404.37858.40

  • 233

    InoueMIwasakiMOtaniTSasazukiSNodaMTsuganeS. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med (2006) 166(17):1871–7.10.1001/archinte.166.17.1871

  • 234

    LuoJPhillipsLLiuSWactawski-WendeJMargolisKL. Diabetes, diabetes treatment, and risk of thyroid cancer. J Clin Endocrinol Metab (2016) 101(3):1243–8.10.1210/jc.2015-3901

  • 235

    HsuIRKimSPKabirMBergmanRN. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr (2007) 86(3):s867–71.

  • 236

    CelaniMFBonatiMEStucciN. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus. Diabetes Res (1994) 27(1):15–25.

  • 237

    DangCVSemenzaGL. Oncogenic alterations of metabolism. Trends Biochem Sci (1999) 24(2):68–72.10.1016/S0968-0004(98)01344-9

  • 238

    CoweySHardyRW. The metabolic syndrome: a high-risk state for cancer?Am J Pathol (2006) 169(5):1505–22.10.2353/ajpath.2006.051090

  • 239

    GiovannucciEHarlanDMArcherMCBergenstalRMGapsturSMHabelLAet alDiabetes and cancer: a consensus report. Diabetes Care (2010) 33(7):1674–85.10.2337/dc10-0666

  • 240

    ButADe BruinMLBazelierMTHjellvikVAndersenMAuvinenAet alCancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia (2017).10.1007/s00125-017-4312-5

  • 241

    TsengCH. Treatment with human insulin does not increase thyroid cancer risk in patients with type 2 diabetes. Eur J Clin Invest (2014) 44(8):736–42.10.1111/eci.12290

  • 242

    SuissaSAzoulayLDell’AnielloSEvansMVoraJPollakM. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia (2011) 54(9):2254–62.10.1007/s00125-011-2190-9

  • 243

    RuiterRVisserLEvan Herk-SukelMPCoeberghJWHaakHRGeelhoed-DuijvestijnPHet alRisk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia (2012) 55(1):51–62.10.1007/s00125-011-2312-4

  • 244

    PeetersPJBazelierMTLeufkensHGAuvinenAvan StaaTPde VriesFet alInsulin glargine use and breast cancer risk: associations with cumulative exposure. Acta Oncol (2016) 55(7):851–8.10.3109/0284186X.2016.1155736

  • 245

    SmithUGaleEA. Does diabetes therapy influence the risk of cancer?Diabetologia (2009) 52(9):1699–708.10.1007/s00125-009-1441-5

  • 246

    MannucciEMonamiMBalziDCresciBPalaLMelaniCet alDoses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 33(9):1997–2003.10.2337/dc10-0476

  • 247

    CurrieCJ. The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings. Diabetologia (2009) 52(10):2234–5; author reply 2236–9.10.1007/s00125-009-1477-6

  • 248

    BowkerSLMajumdarSRVeugelersPJohnsonJA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 29(2):254–8.10.2337/dc06-0997

  • 249

    YangXKoGTSoWYMaRCYuLWKongAPet alAssociations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes (2010) 59(5):1254–60.10.2337/db09-1371

  • 250

    ChangCHLinJWWuLCLaiMSChuangLM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab (2012) 97(7):E1170–5.10.1210/jc.2012-1162

  • 251

    SimoRPlana-RipollOPuenteDMorrosRMundetXVilcaLMet alImpact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PLoS One (2013) 8(11):e79968.10.1371/journal.pone.0079968

  • 252

    LinCMHuangHLChuFYFanHCChenHAChuDMet alAssociation between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: a nationwide, population-based cohort study. PLoS One (2015) 10(5):e0125421.10.1371/journal.pone.0125421

  • 253

    ChiuCCHuangCCChenYCChenTJLiangYLinSJet alIncreased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med (2013) 52(9):939–46.10.2169/internalmedicine.52.8276

  • 254

    FilippatosTDLiberopoulosENElisafMS. Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 6(1):29–41.10.1177/2042018814558243

  • 255

    KnudsenLB. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl (2010) 167:4–11.10.1111/j.1742-1241.2010.02499.x

  • 256

    SakulHPratleyRCardonLRavussinEMottDBogardusC. Familiality of physical and metabolic characteristics that predict the development of non-insulin-dependent diabetes mellitus in Pima Indians. Am J Hum Genet (1997) 60(3):651–6.

  • 257

    ElbeinSCHasstedtSJWegnerKKahnSE. Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab (1999) 84(4):1398–403.10.1210/jcem.84.4.5604

  • 258

    WatanabeRMValleTHauserERGhoshSErikssonJKohtamakiKet alFamiliality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. Hum Hered (1999) 49(3):159–68.10.1159/000022865

  • 259

    LehtovirtaMKaprioJForsblomCErikssonJTuomilehtoJGroopL. Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins. Diabetologia (2000) 43(3):285–93.10.1007/s001250050046

  • 260

    LinHFBoden-AlbalaBJuoSHParkNRundekTSaccoRL. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia (2005) 48(10):2006–12.10.1007/s00125-005-1892-2

  • 261

    BelliaAGiardinaELauroDTesauroMDi FedeGCusumanoGet al“The Linosa Study”: epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. Nutr Metab Cardiovasc Dis (2009) 19(7):455–61.10.1016/j.numecd.2008.11.002

  • 262

    CarmelliDCardonLRFabsitzR. Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments?Am J Hum Genet (1994) 55(3):566–73.

  • 263

    HardyOTCzechMPCorveraS. What causes the insulin resistance underlying obesity?Curr Opin Endocrinol Diabetes Obes (2012) 19(2):81–7.10.1097/MED.0b013e3283514e13

  • 264

    BoothFWRobertsCKLayeMJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol (2012) 2(2):1143–211.10.1002/cphy.c110025

  • 265

    KahnSEHullRLUtzschneiderKM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature (2006) 444(7121):840–6.10.1038/nature05482

  • 266

    CaliffR. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J Suppl (2003) 5(Suppl C):C13–8.10.1016/S1520-765X(03)90045-9

  • 267

    Darnton-HillINishidaCJamesWP. A life course approach to diet, nutrition and the prevention of chronic diseases. Public Health Nutr (2004) 7(1A):101–21.10.1079/PHN2003584

  • 268

    StockleyL. Toward public health nutrition strategies in the European Union to implement food based dietary guidelines and to enhance healthier lifestyles. Public Health Nutr (2001) 4(2A):307–24.

  • 269

    TrubswasserUBrancaF. Nutrition policy is taking shape in Europe. Public Health Nutr (2009) 12(3):295–306.10.1017/S1368980009004753

  • 270

    KnowlerWCBarrett-ConnorEFowlerSEHammanRFLachinJMWalkerEAet alReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 346(6):393–403.10.1056/NEJMoa012512

  • 271

    WaddenTAWebbVLMoranCHBailerBA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation (2012) 125(9):1157–70.10.1161/CIRCULATIONAHA.111.039453

  • 272

    McLaughlinTAbbasiFKimHSLamendolaCSchaafPReavenG. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. Metabolism (2001) 50(7):795–800.10.1053/meta.2001.24210

  • 273

    AnderssonMKarumbunathanVZimmermannMB. Global iodine status in 2011 and trends over the past decade. J Nutr (2012) 142(4):744–50.10.3945/jn.111.149393

  • 274

    RenaGHardieDGPearsonER. The mechanisms of action of metformin. Diabetologia (2017) 60(9):1577–85.10.1007/s00125-017-4342-z

  • 275

    DecensiAPuntoniMGoodwinPCazzanigaMGennariABonanniBet alMetformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 3(11):1451–61.10.1158/1940-6207.CAPR-10-0157

  • 276

    NotoHGotoATsujimotoTNodaM. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 7(3):e33411.10.1371/journal.pone.0033411

  • 277

    Heckman-StoddardBMGandiniSPuntoniMDunnBKDeCensiASzaboE. Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol (2016) 43(1):123–33.10.1053/j.seminoncol.2015.09.009

  • 278

    TsengCH. Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. PLoS One (2014) 9(10):e109852.10.1371/journal.pone.0109852

  • 279

    BeckerCJickSSMeierCRBodmerM. No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study. BMC Cancer (2015) 15:719.10.1186/s12885-015-1719-6

  • 280

    RezzonicoJRezzonicoMPusiolEPitoiaFNiepomniszczeH. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord (2011) 9(1):69–75.10.1089/met.2010.0026

  • 281

    KarimifarMAminorroayaAAminiMMirfendereskiTIrajBFeiziAet alEffect of metformin on thyroid stimulating hormone and thyroid volume in patients with prediabetes: a randomized placebo-controlled clinical trial. J Res Med Sci (2014) 19(11):1019–26.

  • 282

    AnilCKutAAtesagaogluBNarABascil TutuncuNGursoyA. Metformin decreases thyroid volume and nodule size in subjects with insulin resistance: a preliminary study. Med Princ Pract (2016) 25(3):233–6.10.1159/000442821

  • 283

    MengXXuSChenGDerwahlMLiuC. Metformin and thyroid disease. J Endocrinol (2017) 233(1):R43–51.10.1530/JOE-16-0450

  • 284

    Ben SahraILe Marchand-BrustelYTantiJFBostF. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?Mol Cancer Ther (2010) 9(5):1092–9.10.1158/1535-7163.MCT-09-1186

  • 285

    VigerskyRAFilmore-NassarAGlassAR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab (2006) 91(1):225–7.10.1210/jc.2005-1210

  • 286

    FournierJPYinHYuOHAzoulayL. Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus. CMAJ (2014) 186(15):1138–45.10.1503/cmaj.140688

  • 287

    PandiniGMineoRFrascaFRobertsCTJrMarcelliMVigneriRet alAndrogens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 65(5):1849–57.10.1158/0008-5472.CAN-04-1837

  • 288

    MalaguarneraRSaccoAMorcavalloASquatritoSMigliaccioAMorrioneAet alMetformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology (2014) 155(4):1207–21.10.1210/en.2013-1925

  • 289

    LeiYYiYLiuYLiuXKellerETQianCNet alMetformin targets multiple signaling pathways in cancer. Chin J Cancer (2017) 36(1):17.10.1186/s40880-017-0184-9

  • 290

    SosnickiSKapralMWeglarzL. Molecular targets of metformin antitumor action. Pharmacol Rep (2016) 68(5):918–25.10.1016/j.pharep.2016.04.021

  • 291

    DowlingRJGoodwinPJStambolicV. Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 9:33.10.1186/1741-7015-9-33

  • 292

    El-MirMYNogueiraVFontaineEAveretNRigouletMLeverveX. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem (2000) 275(1):223–8.10.1074/jbc.275.1.223

  • 293

    MalkiAYoussefA. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res (2011) 19(6):275–85.10.3727/096504011X13021877989838

  • 294

    KimHGHienTTHanEHHwangYPChoiJHKangKWet alMetformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol (2011) 162(5):1096–108.10.1111/j.1476-5381.2010.01101.x

  • 295

    HwangYPJeongHG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol (2010) 160(5):1195–211.10.1111/j.1476-5381.2010.00762.x

  • 296

    KumarNDeyCS. Metformin enhances insulin signalling in insulin-dependent and -independent pathways in insulin resistant muscle cells. Br J Pharmacol (2002) 137(3):329–36.10.1038/sj.bjp.0704878

  • 297

    HeLSabetADjedjosSMillerRSunXHussainMAet alMetformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell (2009) 137(4):635–46.10.1016/j.cell.2009.03.016

  • 298

    ConkrightMDCanettieriGScreatonRGuzmanEMiragliaLHogeneschJBet alTORCs: transducers of regulated CREB activity. Mol Cell (2003) 12(2):413–23.10.1016/j.molcel.2003.08.013

  • 299

    ScreatonRAConkrightMDKatohYBestJLCanettieriGJeffriesSet alThe CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell (2004) 119(1):61–74.10.1016/j.cell.2004.09.015

  • 300

    OwenMRDoranEHalestrapAP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J (2000) 348(Pt 3):607–14.10.1042/0264-6021:3480607

  • 301

    WilcockCBaileyCJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica (1994) 24(1):49–57.10.3109/00498259409043220

  • 302

    CarvalhoCCorreiaSSantosMSSeicaROliveiraCRMoreiraPI. Metformin promotes isolated rat liver mitochondria impairment. Mol Cell Biochem (2008) 308(1–2):75–83.10.1007/s11010-007-9614-3

  • 303

    AndrzejewskiSGravelSPPollakMSt-PierreJ. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab (2014) 2:12.10.1186/2049-3002-2-12

  • 304

    ChenGXuSRenkoKDerwahlM. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab (2012) 97(4):E510–20.10.1210/jc.2011-1754

  • 305

    IliopoulosDHirschHAStruhlK. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 71(9):3196–201.10.1158/0008-5472.CAN-10-3471

  • 306

    RochaGZDiasMMRopelleEROsorio-CostaFRossatoFAVercesiAEet alMetformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res (2011) 17(12):3993–4005.10.1158/1078-0432.CCR-10-2243

  • 307

    PetrushevBTomuleasaCSoritauOAldeaMPopTSusmanSet alMetformin plus PIAF combination chemotherapy for hepatocellular carcinoma. Exp Oncol (2012) 34(1):17–24.

  • 308

    HanBCuiHKangLZhangXJinZLuLet alMetformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway. Tumour Biol (2015) 36(8):6295–304.10.1007/s13277-015-3315-4

  • 309

    Klubo-GwiezdzinskaJCostelloJJrPatelABauerAJensenKMeteMet alTreatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab (2013) 98(8):3269–79.10.1210/jc.2012-3799

  • 310

    JangEKKimWGKwonHChoiYMJeonMJKimTYet alMetformin is associated with a favorable outcome in diabetic patients with cervical lymph node metastasis of differentiated thyroid cancer. Eur Thyroid J (2015) 4(3):181–8.10.1159/000437365

  • 311

    KahnSEHaffnerSMHeiseMAHermanWHHolmanRRJonesNPet alGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 355(23):2427–43.10.1056/NEJMoa066224

  • 312

    JuurinenLKotronenAGranerMYki-JarvinenH. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab (2008) 93(1):118–24.10.1210/jc.2007-1825

  • 313

    PhielixESzendroediJRodenM. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci (2011) 32(10):607–16.10.1016/j.tips.2011.06.006

  • 314

    TiikkainenMHakkinenAMKorsheninnikovaENymanTMakimattilaSYki-JarvinenH. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes (2004) 53(8):2169–76.10.2337/diabetes.53.8.2169

  • 315

    HevenerALReichartDJanezAOlefskyJ. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats. Diabetes (2001) 50(10):2316–22.10.2337/diabetes.50.10.2316

  • 316

    ShibuyaAWatanabeMFujitaYSaigenjiKKuwaoSTakahashiHet alAn autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care (1998) 21(12):2140–3.10.2337/diacare.21.12.2140

  • 317

    NissenSEWolskiK. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 356(24):2457–71.10.1056/NEJMoa072761

  • 318

    TsengCH. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes. Ann Med (2013) 45(8):539–44.10.3109/07853890.2013.851865

  • 319

    VellaVNicolosiMLGiulianoSBellomoMBelfioreAMalaguarneraR. PPAR-gamma agonists as antineoplastic agents in cancers with dysregulated IGF axis. Front Endocrinol (2017) 8:31.10.3389/fendo.2017.00031

  • 320

    TsengCH. Pioglitazone and thyroid cancer risk in Taiwanese patients with type 2 diabetes 2. J Diabetes (2014) 6(5):448–50.10.1111/1753-0407.12149

  • 321

    FrascaFPandiniGVigneriRGoldfineID. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis (2003) 17:73–89.10.3233/BD-2003-17108

  • 322

    BuckEGokhalePCKoujakSBrownEEyzaguirreATaoNet alCompensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther (2010) 9(10):2652–64.10.1158/1535-7163.MCT-10-0318

  • 323

    BelfioreAMalaguarneraRVellaVLawrenceMCSciaccaLFrascaFet alInsulin receptor isoforms in physiology and disease: an updated view. Endocr Rev (2017) 38(5):379–431.10.1210/er.2017-00073

  • 324

    BanerjiSCibulskisKRangel-EscarenoCBrownKKCarterSLFrederickAMet alSequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 486(7403):405–9.10.1038/nature11154

  • 325

    ImielinskiMBergerAHHammermanPSHernandezBPughTJHodisEet alMapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 150(6):1107–20.10.1016/j.cell.2012.08.029

  • 326

    ScottLMRebelVI. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. J Natl Cancer Inst (2013) 105(20):1540–9.10.1093/jnci/djt257

  • 327

    BonnalSVigevaniLValcarcelJ. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov (2012) 11(11):847–59.10.1038/nrd3823

  • 328

    KaraIPoggiMBonardoBGoversRLandrierJFTianSet alThe paired basic amino acid-cleaving enzyme 4 (PACE4) is involved in the maturation of insulin receptor isoform B: an opportunity to reduce the specific insulin receptor-dependent effects of insulin-like growth factor 2 (IGF2). J Biol Chem (2015) 290(5):2812–21.10.1074/jbc.M114.592543

  • 329

    RoebroekAJTaylorNALouagieEPauliISmeijersLSnellinxAet alLimited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem (2004) 279(51):53442–50.10.1074/jbc.M407152200

  • 330

    ZhuJVan de VenWJVerbiestTKoeckelberghsGChenCCuiYet alPolyphenols can inhibit furin in vitro as a result of the reactivity of their auto-oxidation products to proteins. Curr Med Chem (2013) 20(6):840–50.10.2174/092986713805076702

  • 331

    VivacquaADe MarcoPBelfioreAMaggioliniM. Recent advances on the role of microRNAs in both insulin resistance and cancer. Curr Pharm Des (2017) 23(25):3658–66.10.2174/1381612823666170622105123

  • 332

    ScagliottiGVNovelloS. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev (2012) 38(4):292–302.10.1016/j.ctrv.2011.07.008

  • 333

    PrinceSNFoulstoneEJZaccheoOJWilliamsCHassanAB. Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor. Mol Cancer Ther (2007) 6(2):607–17.10.1158/1535-7163.MCT-06-0509

  • 334

    FragoSNichollsRDStricklandMHughesJWilliamsCGarnerLet alFunctional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist. Proc Natl Acad Sci U S A (2016) 113(20):E2766–75.10.1073/pnas.1513023113

  • 335

    WangNRayesRFElahiSMLuYHancockMAMassieBet alThe IGF-Trap: novel inhibitor of carcinoma growth and metastasis. Mol Cancer Ther (2015) 14(4):982–93.10.1158/1535-7163.MCT-14-0751

  • 336

    ScheenAJ. SGLT2 inhibitors: benefit/risk balance. Curr Diab Rep (2016) 16(10):92.10.1007/s11892-016-0789-4

  • 337

    AvogaroAGiaccariAFiorettoPGenoveseSPurrelloFGiorginoFet alA consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol (2017) 10(7):763–72.10.1080/17512433.2017.1322507

  • 338

    HaugenBRAlexanderEKBibleKCDohertyGMMandelSJNikiforovYEet al2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid (2016) 26(1):1–133.10.1089/thy.2015.0020

Summary

Keywords

insulin resistance, insulin, thyroid cancer, obesity, type 2 diabetes, insulin growth factor, metformin, insulin sensitizers

Citation

Malaguarnera R, Vella V, Nicolosi ML and Belfiore A (2017) Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?. Front. Endocrinol. 8:314. doi: 10.3389/fendo.2017.00314

Received

04 September 2017

Accepted

30 October 2017

Published

14 November 2017

Volume

8 - 2017

Edited by

Haim Werner, Tel Aviv University, Israel

Reviewed by

Pierre De Meyts, de Duve Institute, Belgium; Eddy Karnieli, Technion Israel Institute of Technology, Israel

Updates

Copyright

© 2017 Malaguarnera, Vella, Nicolosi and Belfiore.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Veronica Vella, ; Antonino Belfiore,

†These authors have equally contributed to this work.

Specialty section: This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics